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ABSTRACT 
TITLE OF THE STUDY:  “The prognostic value of T peak – T end interval on the surface 
Electrocardiogram in patients undergoing reperfusion therapy for ST- segment Elevation 
Myocardial Infarction” 
 
INTRODUCTION:  Arrhythmic events are one of the leading causes of death in patients after 
myocardial infarction.  Repolarization abnormalities on the surface ECG has been associated 
with increased arrhythmic risk. We sought to investigate the effect of reperfusion, on Tpeak-
Tend interval (TpTe), a marker of repolarization and also its predictive value for 30 day 
mortality, heart failure and arrhythmias. 
OBJECTIVES:   We aimed to analyze the effect of reperfusion of infarct related artery on the 
TpTe interval determined on the surface 12 lead ECG. We also studied the association of Major 
adverse cardiac events (MACE) with repolarization abnormality in the ECG. The correlation 
between TpTe interval and QT dispersion was also determined. 
METHODS:  Patients with new onset STEMI treated with thrombolysis or primary/ rescue PCI 
were included.  Digital ECGs at 50 mm/sec speed and 20 mm/mV gain filtered at 0.50–150Hz 
were taken before and after reperfusion therapy.   TpTe interval was measured in leads with 
limited ST-segment deviation and so also the QTc. Echocardiography was done before hospital 
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discharge for all patients. Angiographic parameters of patients undergoing primary or rescue PCI 
were recorded.  All patients were followed up at 30 days.  
RESULTS:    From June 2013 to December 2013, total of 216 patients were included of which 
183 were males (85.1%).  The mean age was 54.86 years (range 24-80 years).  One hundred and 
thirteen patients underwent primary PCI (52.3%), 57 underwent lysis (26.4%) and remaining 
46(21.3%) had rescue PCI.  Thirty day Mortality was 5.1 % (11 patients).  
The median pre TpTe interval was 84.5ms and the 25th, 50th and 75th percentiles were 80, 84 and 
100 ms respectively. The median post TpTe intervals were 76.7ms (64, 76.7 and 80ms), 75ms 
(60, 75 and 80ms) and 73.3ms (66.7, 73.3 and 80ms) respectively in the primary PCI, 
thrombolysis and rescue PCI groups. There was statistically significant reduction in TpTe 
interval at 90 minutes following reperfusion (p values of 0.0001, 0.0001 and 0.004 respectively). 
This reduction was uniformly seen in all the treatment arms.   
Of the 216 patients, 210 were followed up at 30 days. Six patients were lost to follow up.  Eleven 
patients died 11(5.1%) patients had died.  The pre TpTe interval of more than 100 ms was 
associated with increased risk of ventricular arrhythmias (OR 13.21, 95% CI 1.16 – 150.57). 
However, it did not predict mortality at 30 days (OR – 1.405, 95% CI – 0.288 – 6.842) or heart 
failure in the 8 patients at follow up. (OR 2.14, 95% CI 0.412-11.148). There was no correlation 
between the TpTe interval and QTc dispersion. After adjusting for established risk factors, TpTe 
interval difference (pre – post) was found to be significantly associated with duration of chest 
pain and Killip class. 
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CONCLUSION:  In patients with STEMI undergoing reperfusion, the TpTe interval was 
significantly reduced after reperfusion therapy (either primary PCI or thrombolysis).  Pre-
reperfusion TpTe predicted the risk of arrhythmias at 30 days. However, it did not predict 
subsequent all cause mortality and heart failure at 30 days.  QT dispersion did not correlate with 
changes in TpTe interval at 90 minutes following reperfusion. 
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CHAPTER 1 
INTRODUCTION 
The modern “reperfusion era” of coronary care was introduced by the intra-venous fibrinolysis, 
and with increased use of aspirin supplemented by development of primary percutaneous 
coronary intervention, the case fatality rate of STEMI has reduced significantly.(1,2) However, it 
continues to be a major public health problem in the industrialized world and is slated to rise in 
the developing countries.(3)  
The aim of treatment of STEMI is mechanical reperfusion.  In this context, mechanical 
reperfusion by primary percutaneous coronary intervention (primary PCI) has become the first 
standard option for the treatment of STEMI, over thrombolysis.(4) 
One of the important long term goals of reperfusion strategy is to prevent sudden cardiac death 
which is most often related to ventricular arrhythmias.  Patients with abnormal repolarization 
have been shown to have increased risk of sudden death.(5)  Repolarization of the myocardium is 
dependent on the perfusion.(6)  
Towards this end, electrophysiological characterizations of post-STEMI patients by the indices 
of repolarization on the surface electrocardiogram (ECG) have shown clinical promise for the 
prediction of death and malignant arrhythmias.  In the standard 12 lead ECG, the interval from 
the peak (Tp) to the end (Te) of the T wave (TpTe) has been proposed to represent repolarization 
dispersion in the heart.(7)  The corrected QT interval dispersion (CQTD) is another index of 
5 
 
repolarization on the 12 lead ECG.(8) It is the difference between the maximum and the 
minimum QT duration on the 12 lead surface ECG, corrected to the heart rate.  
RELEVANCE OF THE STUDY 
There have been very few studies which have looked at TpTe post primary PCI in patients with 
STEMI and none that have looked at the effect of thrombolysis on TpTe. Previous studies have 
shown varying results of the mechanical reperfusion of the infarct-related arteries on CQTD.    
(5, 9)  
The purpose of the present study is to analyze prospectively, in patients with STEMI undergoing 
reperfusion therapy, the acute effects of the reperfusion of the infarct related artery on the TpTe 
and the CQTd. It will also analyze the effect of reperfusion on this parameter and also its 
predictive value for 30 day mortality. The study will also compare the results of reperfusion 
therapy (primary PCI versus thrombolysis) on repolarization indices. 
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CHAPTER 2 
OBJECTIVES 
 To analyze prospectively, in patients with STEMI undergoing reperfusion therapy, the 
effect of reperfusion on the Tpeak-Tend interval on the surface 12 lead 
Electrocardiogram. 
 To study the association of Major Adverse Cardiac with repolarization abnormality in the 
ECG. 
 To study the correlation between TpTe interval and QT dispersion. 
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CHAPTER 3 
REVIEW OF LITERATURE 
DEFINITION OF STEMI   
The World Health Organization and American Heart Association have given a revised definition 
for Myocardial Infarction.  Either of the following criteria satisfies the diagnosis for acute, 
evolving or recent STEMI: 
1) Typical rise and/or fall of biochemical markers of myocardial necrosis with at least one 
of the following :  
a. Ischemic symptoms 
b. Development of pathologic Q waves in the ECG 
c. Electrocardiographic changes indicative of ischaemia (ST segment elevation or 
depression) 
d. Imaging evidence of new loss of myocardium or new regional wall motion 
abnormality 
2) Pathologic findings of an acute Myocardial Infarction 
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RISK STRATIFICATION AFTER STEMI  
Risk stratification after STEMI occurs in several stages – initial presentation, in-hospital course 
and at the time of hospital discharge (Figure 3.1 and Table 3.1).  
Certain demographic and historical factors portends a worse prognosis in patients with STEMI, 
which includes (5,11–14)  
 Female gender 
 Age > 65 years 
 History of Diabetes Mellitus (>40% increase in adjusted risk of death at 30 days)  
 Prior angina pectoris 
 Previous MI 
 Development of Heart failure after MI  entails a higher risk of sudden cardiac death 
 Recurrent ischaemia and infarction following STEMI 
 Anterior wall (compared to inferior wall )  
 RV infarction complicating inferior wall STEMI (compared to inferior wall alone)  
 Multiple leads showing ST-segment elevation and a high sum of ST-segment elevation 
 Persistent advanced heart block (type II second-degree or third-degree AV block) 
 New intraventricular conduction disturbances (bifascicular or trifascicular) 
 Persistent horizontal or down sloping ST-segment depression 
 Q waves in multiple leads 
 ST-segment depressions in anterior leads in patients with inferior MI 
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 Atrial arrhythmias, especially AF 
 Patients with abnormal repolarization 
The TIMI (Thrombolysis for Myocardial Infarction) risk score for predicting 30-day 
mortality is as shown in Table 3.1 & Figure 3.1.(15) 
TABLE 3. 1- THROMBOLYSIS FOR MYOCARDIAL INFARCTION (TIMI) RISK SCORE 
Variable Risk Score 
Age 65-74/>75 years 2/3 points 
Systolic BP <100 mm Hg 3 points 
Heart rate >100 bpm 2 points 
Killip class 2-4 2 points 
Anterior STEMI or LBBB 1 point 
Diabetes, Hypertension, h/o angina 1 point 
Weight <67 kg 1 point 
Time to treatment>4 hours 1 point 
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Depending on the risk score, the 30 day Mortality varies. 
FIGURE 3. 1-TIMI RISK SCORE DEPICTING 30 DAY MORTALITY FOR ST SEGMENT ELEVATION MYOCARDIAL 
INFARCTION 
 
Courtesy: Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk 
score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at 
presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. 
Circulation. 2000 Oct 24;102(17):2031–7 
 
Both short- and long-term survival after STEMI depend on three factors(5,16):  
1) Resting LV function(most important)  
2) Residual potentially ischemic myocardium 
3) Susceptibility to serious ventricular arrhythmias 
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STEMI AND REPERFUSION THERAPY 
STEMI is a major cause of mortality and morbidity. In randomized trials, the short-term 
mortality rate in patients who receive aggressive pharmacologic reperfusion therapy is 6.5-7.5% 
(17).  However, observational data bases suggest that mortality rate of STEMI patients in the 
community is 15-20%.(18)  Considerable variation exists in the management and outcomes of 
patients with STEMI.(19) 
Almost all STEMIs are due to coronary atherosclerosis, usually with superimposed coronary 
thrombosis.  Plaque disruption in the culprit vessel produces complete occlusion of the infarct-
related artery.  As there is progressive loss of functioning myocytes with persistent occlusion of 
the infarct-related artery in STEMI, restoration of blood flow to the infarct zone is of paramount 
importance.  Otherwise, left ventricular dilation and ultimate death ensues through a combination 
of pump failure and electrical instability.  Early reperfusion shortens the duration of coronary 
occlusion, minimizes the degree of ultimate left ventricular dilation and dysfunction and reduces 
the probability that the STEMI patient will develop pump failure and malignant ventricular 
tachyarrhythmias.  
It is generally accepted that primary PCI is the preferred option for reperfusion, provided it can 
be delivered in a timely fashion by  an experienced operator(>75 PCI procedures/year) and team 
(at least 200  PCI procedures/year, including at least 36 primary PCI procedures/year).(20)  
Although late spontaneous reperfusion occurs in some patients, thrombotic occlusion persists in 
most patients of STEMI.  
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The goal of treatment of STEMI is myocardial reperfusion.(21)  Mechanical reperfusion by 
primary PCI has become the first choice of treatment.  The successful recanalization of the 
epicardial coronaries are important, but the microvascular flow determines the amount of 
myocardium salvaged and long term prognosis.  
An invasive strategy (primary PCI) is generally preferred if (20) :  
1. Skilled PCI laboratory is available with surgical backup 
a. Medical contact-to-balloon or door-to-balloon  <90 minutes 
b. (Door-to-balloon) -  (Door-to-needle) time  <60 minutes 
2. High risk from STEMI 
a. Cardiogenic shock 
b. Killip class 3 or 4 
3. Contraindications to fibrinolysis, including increased risk of bleeding and ICH 
4. Late presentation, i.e., symptom onset > 3 hours ago 
5. Diagnosis of STEMI is in doubt 
Each 30-minute delay from the symptom onset to PCI increases the relative risk (RR) of 1-year 
mortality by 8%. (22) 
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MEASURES OF REPERFUSION 
Several techniques can evaluate the adequacy of myocardial perfusion. Electrocardiographic ST-
segment resolution (STR) is a strong predictor of outcome in STEMI patients.(16)  ST segment 
resolution reflects flow at the microvascular level and not epicardial coronary flow, and therefore 
provides better prognostic information than angiogram alone.  The absence of early STR after 
primary PCI identifies patients with higher risk of LV dysfunction and mortality, presumably due 
to microvascular damage.  The 12 lead ECG is a marker of the biologic integrity of myocytes in 
the infarct zone and can reflect inadequate myocardial perfusion, even in the presence of TIMI 
grade III flow.  
To provide a level of standardization, most investigators describe the flow in the infarct vessel 
according to Thrombolysis in Myocardial Infarction (TIMI) trial grading system (23): 
 Grade 0 - Complete occlusion of the infarct-related artery 
 Grade 1 - Some penetration of the contrast material beyond the point of obstruction, but 
without perfusion of the distal coronary bed 
 Grade 2 – Perfusion of the entire infarct vessel into the distal bed but with delayed flow 
compared with a normal artery 
 Grade 3 – Full perfusion of the infarct vessel with normal flow 
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TIMI grade 3 flows is far superior to grade 2 with regards to (21) 
 Infarct size reduction 
 Short- and long-term mortality benefit 
Therefore, TIMI grade 3 is the goal targeted while opening up an infarct-related artery by 
primary PCI. (24)  
In patients with STEMI, reperfusion therapy aims to improve actual myocardial reperfusion in 
the infarct zone.  Normalization of myocardial perfusion can be impeded by microvascular 
damage and reperfusion injury.   
An angiographic method for assessing myocardial perfusion is the TMP grade (TIMI myocardial 
perfusion grade developed by Gibson and coworkers).  Abnormal TMP grade correlate with 
mortality risk even in the presence of TIMI 3 flow or a normal TIMI frame count.(25) 
 TMP grade 0 – No or minimal blush 
 TMP grade 1 – Stain present, blush persists on next injection 
 TMP grade 2 – Contrast strongly persistent at the end of washout, gone by next injection 
 TMP grade 3 – Normal ground glass appearance of blush, contrast mildly persistent at end of 
washout 
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SUDDEN CARDIAC DEATH POST STEMI 
After STEMI, patients are at greatest risk of sudden cardiac death caused by malignant 
ventricular arrhythmias over the first 1-2 years after the index event.(26)  Several techniques 
have been proposed to risk stratify patients, which include the following 
 QT dispersion (variability of QT intervals between ECG leads) 
 Holter monitoring 
 Invasive electrophysiological testing 
 Recoding signal-averaged ECG (a measure of delayed, fragmented conduction in the infarct 
zone) 
 Measuring heart rate variability (beat to beat variability in R-R intervals) 
 Baroreflex sensitivity (slope of a line relating beat to beat change in sinus rate in response to 
alteration of blood pressure) 
 Increased ventricular ectopic activity 
However, these have not proved sufficiently useful in routine clinical practice.(5)  The low 
positive predictive value (<30%) for the noninvasive tests limits their usefulness when viewed in 
isolation.(27) 
16 
 
EFFECT OF STEMI ON REPOLARIZATION  
ST-T WAVE ABNORMALITIES 
Acute myocardial injury has marked effects on myocardial repolarization.  Under normal 
conditions, the ST segment is nearly isoelectric.(28) This happens as almost all healthy 
myocardial cells attain approximately the same potential during the initial to middle phases of 
repolarization, that is,  to the plateau phase of the ventricular action potential.  
 Ischemia has complex time-dependent effects on the electrical properties of myocardial 
cells.(28) The earliest ECG finding during acute severe ischemia is ST-segment deviation due to 
a current of injury (both diastolic and systolic). (27,28)  Severe acute ischemia reduces the 
resting membrane potential, abbreviates the duration of action potential in the ischemic area, and 
decreases the rate of rise and amplitude of phase 0.  All these changes cause a voltage gradient 
between the normal and ischemic zones and leads to current flow between these regions (Figure 
3.2). These resulting currents of injury are represented on the surface ECG by ST deviation.(31) 
FIGURE 3.2 ELECTRICAL SYSTOLE AND 
DIASTOLE 
Courtesy: Braunwald’s heart disease –  
A textbook of Cardiovascular Medicine.  
Chapter 13, Page 150 
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Two basic mechanisms are proposed to explain the ST segment elevation seen with acute 
myocardial injury. (32) 
According to the diastolic current of injury hypothesis, ST-segment elevation is due to the 
negative or downward displacement of the electrical diastolic baseline (the TQ segment of the 
ECG).(27, 28) Ischemic myocardial cells remain relatively depolarized during phase 4 of the 
ventricular action potential (has lower resting membrane potential). These depolarized cells carry 
a negative extracellular charge relative to the repolarized myocardial cells. Thus, during 
electrical diastole, current flows between the partly or completely depolarized ischemic zone and 
the neighboring, normally repolarized, uninjured myocardium. The vector of this injury current 
is directed away from the more negative ischemic zone towards the more positive normal 
myocardium. Thus, the leads overlying an ischemic zone will record a negative deflection during 
electrical diastole and produce TQ-segment depression. This, in turn, appears as ST-segment 
elevation because ECG recorders use AC-coupled amplifiers that automatically compensate for 
the negative TQ-segment. As a result, the ST-segment is proportionately elevated. So the 
diastolic current of injury explains ST-segment elevation as an apparent shift. The true shift, that 
is, the negative TQ-segment is observable only with DC-coupled ECG amplifiers (Figure 
3.3).(31) 
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FIGURE 3.3 PATHOPHYSIOLOGY OF ISCHEMIC ST ELEVATION – DIASTOLIC INJURY CURRENT  
 
Courtesy: Braunwald’s heart disease – A textbook of Cardiovascular Medicine.  Chapter 13, Page 150 
 
The second mechanism proposed is the systolic current of injury theory. According to this 
postulate, ischemic myocardial cells are relatively positive in comparison with the normal cells 
during “electrical systole”. This is due to pathologic early repolarization (shortened action 
potential duration), decreased action potential upstroke velocity and amplitude. As a result, a 
voltage gradient is established between the normal and ischemic zones. The current of injury 
vector is directed towards the ischemic zone resulting in ST segment elevation (Figure 3.4). (31) 
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FIGURE 3.4 PATHOPHYSIOLOGY OF ISCHEMIC ST ELEVATION – SYSTOLIC INJURY CURRENT  
 
 
 
 
Courtesy: Braunwald’s heart disease – A textbook of Cardiovascular Medicine.  Chapter 13, Page 150 
When acute ischemia is transmural, the overall ST vector is shifted in the direction of the 
epicardial layers, producing ST-segment elevation and sometimes hyperacute T waves over the 
ischemic zone.(32) Reciprocal ST segment depression can appear in the ECG leads representing 
the contra-lateral surface of the heart and can occasionally be more prominent than the primary 
ST-segment elevation.  During sub-endocardial ischemia, the overall ST vector shifts towards the 
endocardium and ventricular cavity. This produces ST-segment depression in the anterior 
precordial leads and ST-segment elevation in lead aVR which is the typical finding during 
spontaneous episodes of angina, and symptomatic or silent ischemia induced by exercise or the 
various pharmacologic stress tests. 
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OTHER ISCHEMIC ST –T PATTERNS/ U WAVE CHANGES 
Coronary vasospasm can cause very transient ST-segment elevation which can resolve 
completely within minutes or may be followed by T wave inversion that can persist for hours to 
days. (31) 
Some patients develop deep T wave inversion in multiple precordial leads. This is typically 
found in high-grade stenosis in the proximal LAD (referred to as the LAD-T wave or Wellens T-
wave).  This T wave inversion may be preceded by a transient ST-segment elevation.  
Some patients with baseline ECG abnormality can have paradoxical T wave normalization 
(pseudo normalization) during episodes of acute ischemia.  
Alterations in U wave amplitude or polarity can be seen with acute ischemia or infarction.(34) 
Rarely, U wave inversion may be the earliest ECG sign of an acute coronary syndrome. 
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EFFECT OF STEMI ON QT INTERVAL  
The QT interval is measured from the onset of the QRS complex to the end of the T wave on the 
surface ECG.  QT interval consists of the total duration of ventricular activation and recovery, 
that is, ventricular APD.  Accurately measuring the QT interval is challenging for various 
reasons, including identifying the beginning of the QRS complex and end of the T wave, 
determining which lead(s) to use, adjusting the measured interval for rate, QRS duration and 
gender(35).  The duration of  the QT interval varies widely in the general population(29).  The 
normal QT interval decreases as the heart rate increases, as does the duration of the normal 
ventricular action potential duration and refractoriness.  Thus, the normal range for the QT 
interval is rate-dependent.  Numerous formulas have been proposed to correct the measured QT 
interval for this rate effect. A commonly used formula was developed by Bazett in 1920.  
Corrected QT interval (QTc) = QT/√RR, where the QT and RR intervals are measured in 
seconds. The normal QTc is < 440 ms and is slightly longer in women <40 years.  
The difference between the minimum and maximum QT interval in the same 12-lead surface 
ECG is the QT dispersion. Normally, it can be up to 50 to 65 ms.(36)  CQTd is representative of 
the regional variations in the excitability and recovery of the ischemic myocardium.   
Ischemia results in abrupt reduction in the trans-membrane resting potential (RMP), reduced  
upstroke velocity, amplitude and duration of the action potential.(37)  When ischemic cells 
depolarize to RMP less than -60 mV, they may become inexcitable and the refractoriness of this 
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tissue increases. The consequence is islands of slow conduction and electro-physiologic 
heterogeneity which  creates unidirectional block  and the substrate for reentry.(37) This 
dispersion of refractory periods produced by acute ischaemia manifest as increased QT 
dispersion which is further enhanced by a healed ischemic injury  and  forms the substrate for 
reentrant tachycardias and VF.(38) The time course of repolarization is lengthened after healing 
of ischemic injury and shortened by acute ischemia.   
Different studies have shown that CQTd increases acutely after STEMI.(39) Reperfusion therapy 
restoring flow in the infarct-related artery decreases it. The increased CQTd post STEMI was 
due to lengthening of the maximum QTc and shortening of the minimum QTc.(40)  The CQTd 
reduction was significant when TIMI III flow was achieved. Prolongation of the ventricular 
repolarization (QT interval) is related to the underlying ischaemia post STEMI.(41) 
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EFFECT OF STEMI ON TpTe INTERVAL 
The action potential duration (APD) in the ischemic zone is affected by various metabolic and 
electrochemical changes.  This includes alterations of tissue oxygen levels, pH, and intracellular 
and intercellular electrochemical gradients. There is initially a transient increase followed by 
shortening of the APD.  This is due to reduction in transmembrane potential, APD and upstroke 
velocity of the action potential. All these changes in the ischemic zone are not uniform and leads 
to a steep dispersion of APD across the zone of ischaemia.(42)  Cell-to-cell interactions are also 
abnormal due to closing and redistribution of gap junctions.  Altogether, the dispersion between 
normal non-ischemic and the infarcted tissue is increased during ST elevation MI and this is a 
substrate for various ventricular arrhythmias.  This dispersion is reflected by the increased TpTe 
interval. TpTe interval is easy to determine during the acute phase after STEMI for risk 
stratification. 
The correlation of TpTe with risk of sudden cardiac death in acute coronary syndrome setting is 
debatable. The high negative value of TpTe is comparable to that obtained with T wave alternans 
and signal averaged ECG analyses.(39, 41) The normal TpTe in healthy individuals is below 100 
milli-seconds.(45)  In the study  by Christian Haarmark et al, the pre TpTe interval was 102 ms 
for 91 patients pre primary PCI who survived versus 122 ms in 10 patients who did not.(46)  
However, there are studies where no association was found between pre TpTe interval and 
adverse effects. Zabel et al investigated TpTe interval in 280 patients with MI. There was no 
significant difference in TpTe interval between survivors and non-survivors. Similarly, no 
significant difference in TpTe interval was found between patients with or without arrhythmias 
24 
 
in the follow-up period.(47)  On the contrary, in the study by Bonnemeier et al, TpTe interval 
assessed from Holter recordings hourly was significantly higher in MI patients who had major 
arrhythmias in the first 24 hours after PCI. Also, TpTe interval was shown to fall in the first 4 
hours after PCI, and remained in a  steady level there after.(48) 
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EFFECT OF REPOLARIZATION ON SUDDEN CARDIAC DEATH  
Sudden cardiac death is natural death from cardiac causes, heralded by abrupt loss of 
consciousness within 1 hour of the onset of an acute change in cardiovascular status.(49) 
 The identification of specific clinical markers of risk of SCD in coronary artery disease has been 
a goal for many years.  Coronary artery disease and its consequences account for at least 80% of 
SCDs in Western countries. (50) 
Electrical mechanisms of cardiac arrest and SCD are divided into tachy-arrhythmic and 
bradyarrhythmia-asystolic events. The tachyarrhythmias include VF and pulseless or sustained 
VT. Bradyarrhythmia-asystolic events consist of severe bradycardias, asystole (complete absence 
of electrical activity) or dissociation between abnormal spontaneous electrical activity and 
mechanical function (pulseless electrical activity). (37) 
Electrophysiological characters of the myocardium has shown promise to be able to predict 
malignant arrhythmias.  The various parameters that can be measured are QT interval, signal 
averaged ECG, and T wave alternans.(43)  However, all these values are not validated enough to 
be used in clinical trials.  
Many clinical studies have shown that increased CQTd can identify an increased arrhythmogenic 
risk in patients with long QT syndromes, hypertrophic cardiomyopathy and heart failure.(51)  
However, the same has not been shown in patients with ACS. 
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Prolonged TpTe has been associated with increased risk of arrhythmia and sudden cardiac risk in 
various clinical conditions like LQTS, Brugada syndrome and CPVT. There is evidence of TpTe 
as an index for predicting torsades de pointes in Long QT syndrome.(52)  In hypertrophic 
cardiomyopathy, TpTe is a predictor of sudden cardiac death, but not QT dispersion).(53)  In 
cases of bradyarrhythmia induced torsades, TpTe was the best single predictor of torsades 
compared to QT and QTc. Watanabe et al showed that prolonged TpTe was associated with 
inducibility and spontaneous development of VT in organic heart disease.(54) However, there is 
a paucity of studies determining the predictive value of TpTe in coronary artery disease. 
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CHAPTER 4 
METHODOLOGY 
SETTING 
Department of Cardiology in Christian Medical College, Vellore which is a 2200 bedded, tertiary 
care, multi-specialty teaching hospital in South India.   
STUDY  DESIGN  
This is a prospective study done among patients diagnosed with STEMI in the Department of 
Cardiology in Christian Medical College, Vellore from June 2013 to December 2013.  
INSTITUTIONAL REVIEW BOARD (IRB) AND ETHICS COMMITTEE 
APPROVAL  
The institutional review board of the institution reviewed, discussed and approved the project to 
be conducted as presented in Appendix IV. 
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STUDY GROUP 
Patients diagnosed with new onset STEMI who presented to the chest pain unit and were planned 
for reperfusion were recruited.   
RECRUITMENT  
This was done after the study details were explained in the language that the patient understood. 
The patient was provided with an information sheet and a consent form (Appendix I). Consent 
was taken from patients who are willing to get enrolled in the study. Proforma (Appendix II) was 
filled. 
These patients underwent reperfusion therapy (primary PCI/ Thromobolysis). The method of 
reperfusion was left to the discretion of the clinician.  ECGs (in 50 mm/sec speed and 20 
mm/mV gain) were taken before and after reperfusion (90 minutes after thrombolysis and after 
the patient reached the ward after primary PCI). 
29 
 
 
INCLUSION CRITERIA 
 Patients with STEMI who underwent reperfusion strategy  
 Age group – 18 -80 years 
 Period of recruitment: June 2013 to December 2013 
 The choice of reperfusion therapy was left to the clinician. 
EXCLUSION CRITERIA  
Patients with STEMI who did not undergo reperfusion 
 Age >80 (6 patients excluded)  
 Atrial Fibrillation (2 patients excluded)  
 LBBB (2 patients excluded)  
 qRBBB (10 patients excluded) 
 Prior MI (5 patients excluded) 
 On TPI (3 patients excluded)   
 When the ECG was not interpretable (18 patients excluded) 
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PARAMETERS RECORDED 
CLINICAL VARIABLES  
 Age – in years 
 Sex – male or female 
 Symptom at presentation – chest pain/others 
 Duration of symptoms at presentation – in hours 
 Risk factors  
1) Diabetes Mellitus- on Oral Hypoglycaemic Agents, Insulin or lifestyle modification 
2) Hypertension – on drugs or lifestyle modification 
3) Smoking – currently or in the last 1 year 
4) Dyslipidemia – on drugs or lifestyle modification  
5) Family history of premature CAD – males below 55 years or females below 65 years 
 Killip Class at admission – class I to IV 
 30 day follow up (6 lost) – 
1)  Mortality 
2) Heart failure – requiring re-admission 
3) Arrhythmias -  ECG documentation 
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ELECTROCARDIOGRAPHIC VARIABLES  
Standard 12-lead ECG were recorded at 50 mm/s paper speed and 20 mm/mV gain 
 Site of infarction – anterior or inferior 
 ST elevation – in millivolts 
 Tpeak Tend interval (TpTe) 
TpTe were evaluated in the non-infarct leads, that is, leads with ST deviation < 0.5 mV at 
the J point in the pre-perfusion ECG, to avoid difficulties in assessing T wave markers.  
The intervals between Q onset and T-wave peak (QTp) and T wave end (QTe) were 
manually measured.  The TpTe interval is defined as the difference between the QTe and 
QTp intervals. The averages of all the values were taken. 
 QT Dispersion  
The QT interval was measured manually from the onset of the QRS complex      to the 
end of the T wave, defined as the point of return of the T wave to the isoelectric line or to 
the nadir between the T and U waves (in cases where a U wave is present).  Whenever 
possible, the average measurement of 3 complexes for each lead was taken.  If the end of 
the T wave could not be determined reliably or when the T wave is isoelectric or of very 
low amplitude, the QT measurement was not made in that lead and was excluded from 
the analysis. In order to exclude the effect of heart rates on QT intervals, these were 
corrected using Bazett’s formula.  Corrected QTd is defined as the difference between 
maximum and minimum QTc. 
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ECHOCARDIOGRAPHIC VARIABLES 
All the patients underwent Transthoracic Echocardiography done by Cardiology Registrars 
during Hospital admission.  All the parameters were recorded in accordance with the guidelines 
from the American Society of Echocardiography.  Left ventricular Ejection Fraction was 
measured using Simpson’s method. Measures of diastolic dysfunction were assessed from 2D 
mode and Tissue Doppler mode using pulsed wave Doppler.  
 Left ventricular Ejection Fraction (Simpson’s method) 
 E/A (using Pulsed wave Doppler of Mitral inflow velocity) 
 Mitral deceleration Time- in milliseconds(using Pulsed wave Doppler of Mitral inflow 
velocity)  
 IVRT – in milliseconds (using Tissue Doppler) 
 Septal & lateral e’ velocities (using Tissue Doppler) 
 E/e’  
ANGIOGRAPHIC VARIABLES  
All primary and rescue PCI were done by Cardiology Consultants. All the parameters were 
assessed at the standard 12.5 -16 frames per second. The parameters that were assessed are 
 Vessel(s) involved   
 TIMI flow before and after reperfusion – grade 0 to grade 3 
 TIMI myocardial perfusion grade before and after reperfusion – grade 0 to grade 3 
 Stent used- Drug eluting/ Bare metal stent and size 
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FIGURE 3.5 ALGORITHM OF THE STUDY 
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STATISTICAL ANALYSIS 
Data entry was done using Epidata and exported to Statistical Package for the Social Sciences 
(SPSS) software released in 2009, PASW Statistics for Windows, Version 18.0 Chicago: SPSS 
Inc. Descriptive statistics were tabulated using the SPSS software.  The chi-square test was used 
for comparison of categorical variables.  Odds ratios (OR) and confidence intervals (CI) were 
calculated and p value <0.05 was considered statistically significant.  All reported p values are 2 
sided. Continuous variable were handled with Student t test and Analysis Of Variance test 
(ANOVA). 
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SAMPLE SIZE CALCULATION 
Sample size was calculated using the following formula  
 
This was done using the following values 
Power - 80%  
α-error - 5% 
Pre-test means - 102 ms  
Post-test mean - 106 ms  
Standard deviation - 30 ms 
Sided - 2 
Sample size = 150  
A total of 216 patients were included in the final analysis.  
Values were derived from “The prognostic value of the Tpeak-Tend interval in patients 
undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial 
infarction” study by Haarmark et al (46) 
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CHAPTER 5 
RESULTS 
DEMOGRAPHIC AND CLINICAL CHARACTERISTICS 
During the study period 262 patients were enrolled.  However, only 216 patients met the 
inclusion criteria.  The rest were excluded due to the following reasons 
 Age >80 (6 patients excluded)  
 Atrial Fibrillation (2 patients excluded)  
 LBBB (2 patients excluded)  
 qRBBB (10 patients excluded) 
 Prior MI (5 patients excluded) 
 On TPI (3 patients excluded)  
 The ECG was not interpretable (18 patients excluded) 
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The baseline characteristics of the patients that were included are tabulated in Table 6.1  
TABLE 6.1 BASELINE CHARACTERISTICS OF THE STUDY GROUP 
 Male  
183(84.7%) 
Female 
33(15.3%) 
Total 
216 
Age(Standard Deviation)(in years) 53.4(12.0) 63.2(9.8) 54.9(12.1) 
Chest pain at presentation 180(98.4%) 29(87.9%) 209(96.8%) 
Duration of presenting complaint-Mean and standard 
deviation (in hours) 
5.95(4.9) 9.88(9.7) 6.55(6.10) 
PREEXISTING COMORBIDITIES    
Diabetes Mellitus 65(35.5%) 18(54.5%) 83(38.4%) 
Hypertension 65(35.5%) 14(42.4%) 79(36.6%) 
Smoker 100(54.6%) 0(0%) 100(46.3%) 
Dyslipidemia 7(3.8%) 1(3%) 8(3.7%) 
Family history of Coronary artery disease 6(3.3%) 0(0%) 6(2.8%) 
KILLIP CLASS AT PRESENTATION    
I 149(81.4%) 22(66.7%) 171(79.2%) 
II 21(11.5%) 8(24.2%) 29(13.4%) 
III 5(2.7%) 2(6.1) 7(3.2%) 
IV 8(4.4%) 1(3%) 9(4.2%) 
ECG SITE OF INFARCTION    
Anterior 106(57.9%) 19(57.6%) 125(57.9%) 
Inferior 77(42.1%) 14(42.4%) 91(42.1%) 
INTERVENTION    
Primary PCI 95(51.9%) 18(54.5%) 113(52.3%) 
Lysis 46(25.1%) 11(33.3%) 57(26.4%) 
Rescue PCI 42(23%) 4(12.2%) 46(21.3%) 
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The study group included 216 patients, with 183(85%) males and 33(15%) females (Figure 6.1). 
FIGURE 6.1 SEX DISTRIBUTION OF THE STUDY POPULATION 
 
 
 
 
 
 
The most common age groups that presented with STEMI were in the age group of 51 – 60 years 
followed by 41 -50 years and 61-70 years (Figure 5).  Men presented at a younger age (53.4 
years) compared to women (63.2 years) (Figure 6.2).  
FIGURE 6.2 AGE GROUP DISTRIBUTION IN THE STUDY POPULATION 
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More women presented with atypical symptoms (other than chest pain) compared to men (12.1 
versus 1.6%) (Figure 6.3). 
FIGURE 6.3 CHIEF PRESENTING COMPLAINTS IN THE STUDY POPULATION 
 
Men also presented earlier to the Hospital compared to women with STEMI (5.95 versus 9.88 
hours).  This finding was statistically significant with a   t-test statistic value of -3.567; p <0.05 
(Figure 6.4). Smoking was the most common risk factor for STEMI - present in 54.6% of males. 
FIGURE6.4 DURATION OF SYMPTOMS AT PRESENTATION IN THE STUDY POPULATION 
 
Mean number 
of hours 
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Diabetes Mellitus (men - 35.5% and women - 54.5% with p value of 0.039) and hypertension 
(men – 35.5% and women – 42.4% with p value of 0.448) were the next important risk factors 
and both of these were more prevalent among female patients.  Few patients had dyslipidemia 
(3.7%) or family history of premature CAD (2.8%) (Figure 6.5 & Table 6.1). 
FIGURE 6.5 PRE-EXISTING COMORBIDITIES IN THE STUDY POPULATION 
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Majority of patients presented in Killip class I (79.2%).  Of the rest, 7.6% of patients presented 
in Killip class III and IV (Figure 6.6). 
FIGURE 6.6 KILLIP CLASS IN THE STUDY POPULATION 
 
Fifty eight% of patients were found to have anterior site infarction and 42% were found to have 
inferior wall STEMI on ECG recordings (Figure 6.7). 
FIGURE 6.7 SITE OF INFARCTION IN THE STUDY POPULATION 
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REPERFUSION STRATEGY EMPLOYED 
One hundred and thirteen patients underwent primary PCI, 46 had rescue PCI and 57 underwent 
thrombolysis with streptokinase (Figure 6.8). 
FIGURE 6.8 REPERFUSION STRATEGIES USED IN THE STUDY POPULATION 
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ANGIOGRAPHIC PROFILE OF THE STUDY POPULATION   
Of the 167 patients who underwent primary or rescue PCI, 79(47%), 49(29%) and 39(24%) had 
single, double and triple vessel coronary artery disease respectively (Figure 6.9) 
FIGURE 6.9 ANGIOGRAPHIC FINDINGS IN THE STUDY POPULATION 
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Of the 156 patients who underwent PCI 146(94%) achieved TIMI 3 flow, 7(4%) achieved TIMI 
2, 1(1%) achieved TIMI 1 and 2(1%) patients had no flow (Figure 6.10). 
FIGURE 6.10 CHANGES IN THE THROMBOLYSIS IN MYOCARDIAL INFARCTION (TIMI) FLOW IN THE CULPRIT ARTERY 
AFTER PERCUTANEOUS CORONARY INTERVENTION  
  
2( 1%) 1( 1%) 7(4%)
146(94%)
No flow
I
II
III
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Of the 95 patients, TMP grading after PCI indicated that only 4(4%) had achieved TMP III flow, 
34(36%) TMP II, 42(44%) TMP I and 15(16%) patients had no perfusion (Figure 6.11). 
FIGURE 6.11 CHANGES IN THE TIMI MYOCARDIAL PERFUSION (TMP) GRADING IN THE CULPRIT ARTERY AFTER 
PERCUTANEOUS CORONARY INTERVENTION  
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Of the 143 patients who underwent PCI with stenting 90(63%) had Drug eluting stent and 
53(37%) had Bare metal stent inserted (Figure 6.12).  
FIGURE 6.12 TYPE OF STENT USED IN PRIMARY AND RESCUE PERCUTANEOUS CORONARY INTERVENTION 
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MAJOR ADVERSE CARDIAC EVENTS(MACE) AT 30 DAYS 
There were a total of 11(5.1%) deaths on 30 day follow up.  Of these patients, 8 had heart failure 
and 3 had ventricular arrhythmias (Figure 6.13). 
FIGURE 6.13  MAJOR ADVERSE CARDIAC EVENTS (DEATH, HEART FAILURE AND ARRHYTHMIA)AT 30 DAYS 
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EFFECT OF REPERFUSION ON REPOLARIZATION INDICES 
EFFECT OF REPERFUSION ON TPTE INTERVAL 
There was a significant reduction in duration of repolarization following reperfusion as denoted 
by reduction in TpTe interval in the three intervention groups (primary PCI, lysis and rescue 
PCI)  with p values of < 0.001, 0.001 & 0.005 (Table 6.2). 
TABLE 6.2 PRE AND POST TPTE CORRELATION IN THE INTERVENTION GROUPS - PAIRED SAMPLES STATISTICS 
Intervention  25th 
percentile 
50th 
percentile 
75th 
percentile 
Difference 
in pre & 
post TpTe 
Correlation 
between pre 
& post 
TpTe 
interval(ms) 
Significance level  
(p value) 
Primary 
PCI  
N=113 
80 84 100 13.56 0.544 <0.001* 
Lysis 
N=56 
80 82 98 13.55 0.534 <0.001* 
Rescue PCI 
N=46 
80 86 100 18.68 0.415 <0.005* 
*p<0.05, paired T test statistic 
The median pre TpTe interval was 84.5ms and the 25th, 50th and 75th percentiles were 80, 84 and 
100 ms respectively. The median post TpTe intervals were 76.7ms (64, 76.7 and 80ms), 75ms 
(60, 75 and 80ms) and 73.3ms (66.7, 73.3 and 80ms) respectively in the primary PCI, 
thrombolysis and rescue PCI groups. 
The TpTe interval was reduced by all reperfusion strategies and there was no added advantage 
using any of the treatment options (Table 6.3).  
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TABLE 6.3 DIFFERENCE BETWEEN PRE POST INTERVENTION TPTE INTERVALS BETWEEN DIFFERENT TREATMENT 
GROUPS – ANOVA 
 Sum of Squares df Mean Square F Significance level 
(p value) 
Between Groups 947.87 2 473.93 2.31 .101 
Within Groups 43419.16 212 204.80   
Total 44367.03 214    
 
EFFECT OF REPERFUSION ON QT DISPERSION 
There was a significant increase QT dispersion in the three intervention groups (primary PCI, 
lysis and rescue PCI) with p values of <0.001, 0.002 & 0.009 (Tables 6.4). 
TABLE 6.4 PRE AND POST CQTD CORRELATION IN THE INTERVENTION GROUPS - PAIRED SAMPLES STATISTICS 
Intervention  25th 
percentile 
50th 
percentile 
75th 
percentile 
Difference 
in pre & 
post 
CQTd 
Correlation 
between pre 
& post 
CQTd 
interval(ms) 
Significance level  
(p value) 
Primary 
PCI  
N=113 
31.5 59 86.5 12.45 0.419 <0.001 
Lysis 
N=56 
19.5 46 72 11.81 0.426 <0.002 
Rescue PCI 
N=46 
25 44.5 69.75 11.94 0.387 <0.009 
*p<0.05, paired T test statistic 
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However, there was no correlation in the ∆TpTe interval and ∆CQT dispersion (Table 6.5 & 
Figure 6.14) 
TABLE 6.5 CORRELATION BETWEEN PRE AND POST TPTE AND CQTD 
Difference between pre & post 
intervention TpTe interval (n=215) 
CQTd difference 
Correlation coefficient Spearman's 
rho 
Significance 
level 
(p value) 
.050 0.465 
 
FIGURE 6.14 CORRELATION BETWEEN ∆TPTE AND ∆ CQTD - NON-LINEAR GRAPH  
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EFFECT OF VARIOUS RISK FACTORS ON ∆TpTe INTERVAL 
A multivariate linear regression analysis was performed to study the association of various risk 
factors with the change in TpTe intervals pre and post intervention. ∆TpTe was found to be 
significantly associated with duration of chest pain and Killip class at presentation (Table 6.6) 
 TABLE 6.6 MULTIVARIATE LINEAR REGRESSION ANALYSIS PREDICTING THE ∆TPTE AND VARIOUS RISK FACTORS  
Model B Significance 
level  
(p value) 
95.0% Confidence Interval for 
B 
Lower bound Upper bound 
Constant -2.954 .004 -36.771 -7.335 
Age in years -1.435 .153 -.261 .041 
Male gender 1.281 .202 -1.819 8.565 
Duration of presenting 
complaint(hours) 
-2.620* .009 -.663 -.094 
Diabetes mellitus present -1.229 .221 -5.836 1.355 
Hypertension present .530 .597 -2.613 4.533 
Smoking present -1.313 .191 -6.292 1.263 
Dyslipidemia present .119 .905 -8.348 9.422 
Family history of 
premature CAD present 
-.962 .337 -15.203 5.232 
Killip class(I-IV) -2.340* .020 -5.211 -.445 
Anterior infarct on ECG .388 .698 -2.785 4.151 
*Statistically significant at p <0.05 
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There was no statistically significant correlation in pre TpTe interval and Left Ventricular 
Ejection Fraction (by Simpson’s method) with p value of 0.880 (Table 6.7). 
TABLE 6.7 CORRELATIONS BETWEEN PRE TPTE INTERVAL AND LEFT VENTRICULAR EJECTION FRACTION 
Pre TpTe interval (n=215) 
Left Ventricular Ejection Fraction 
Correlation coefficient  
Spearman's rho 
Significance level 
(p value) 
.010 0.880 
 
There was no statistically significant correlation in pre TpTe interval and extent of coronary 
artery disease with p value of 0.733 (Table 6.8). 
TABLE6.8 CORRELATION BETWEEN PRE TPTE INTERVAL AND EXTENT OF CORONARY ARTERY DISEASE - ANOVA 
 Sum of 
Squares 
df Mean Square F Significance level       
(p value) 
Between 
Groups 
142.22 2 71.11 .311 .733 
Within 
Groups 
38441.53 168 228.81   
Total 38583.76 170    
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MAJOR ADVERSE CARDIAC EVENTS (MACE) AT 30 DAYS AND 
ASSOCIATION WITH TpTe INTERVAL 
Overall 5.1% (11/216) of patients had died by the end of 30 days. The 30 day mortality was 
higher among the patients with Pre TpTe interval above 100 ms (6.7% Versus. 4.8%). This 
however was not statistically significant (Table 6.9).   
TABLE 6.9 ASSOCIATION BETWEEN PRE TPTE AND 30 DAY MORTALITY 
 30 day Mortality Total Odds 
ratio 95% Confidence Interval 
No Yes Lower 
bound 
Upper 
bound 
Upto 100 (ms)  177 9 186 1.405 .288 6.842 
% within 
Based on 
100 
95.2% 4.8% 100.0% 
101 (ms) and 
above 
 28 2 30 
% within 
Based on 
100 
93.3% 6.7% 100.0% 
Total  205 11 216 
% within 
Based on 
100 
94.9% 5.1% 186 
 
Chi square test value = 0.179; p>0.05 
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Of the patients who had died, 8 patients died of heart failure.  The 30 day heart failure was 
higher among the patients with Pre TpTe interval more than 100 ms (6.7% Versus. 3.2%).  This 
association was also not statistically significant (Table 6.10).  
TABLE 6.10 ASSOCIATION BETWEEN PRE TPTE AND 30 DAY HEART FAILURE  
 30 day heart 
failure 
Total Odds 
ratio 
95% Confidence 
Interval 
No Yes Lower 
bound 
Upper 
bound 
Upto 
100 
(ms) 
 180 6 186 2.143 .412 11.148 
% within Based 
on 100 
96.8% 3.2% 100.0% 
101(ms) 
and 
above 
 28 2 30 
% within Based 
on 100 
93.3% 6.7% 100.0% 
Total  208 8 216 
% within 
Based on 100 
96.3% 3.7% 100.0% 
 
Chi square test value = 0.858; p>0.05 
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Overall 1.4% (3/216) of patients had ventricular arrhythmias diagnosed on surface ECG.  All 
three patients died. This was higher among the patients with Pre TpTe interval above 100 ms 
(6.7% Versus. 0.5%) which was statistically significant with an odds ratio of 13.21 (1.16 – 
150.57) (Table 6.11). 
TABLE 6.11 ASSOCIATION BETWEEN PRE TPTE AND 30 DAY ARRHYTHMIA 
 30 day 
arrhythmia 
Total Odds 
ratio 
95% Confidence 
Interval 
No Yes Lower 
bound 
Upper 
bound 
Upto 
100 
(ms) 
 185 1 186 13.214 1.160 150.571 
% within 
Based on 100 
99.5% .5% 100.0% 
101(ms) 
and 
above 
 28 2 30 
% within 
Based on 100 
93.3% 6.7% 100.0% 
Total  213 3 216 
% within 
Based on 
100 
98.6% 1.4% 100.0% 
 
Chi square test value = 7.086; p>0.05 
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CHAPTER6 
DISCUSSION 
BASELINE DEMOGRAPHICS 
In this study, of the 216 patients enrolled, 183 were men (84.7%).  The mean age of presentation 
was 10 years lesser for men compared to women (53.4 versus 63.2 years). This was comparable 
to the longitudinal studies from India. The mean age of the 1459 patients in a study by Kunwar et 
al assessing the reperfusion trends in STEMI was 56.3±11.8 years and that of the CREATE 
registry of acute coronary syndrome was 57.5±12 years(59, 60)   
The average time to admission after symptom onset was 6.5 hours which was almost comparable 
to observations of the CREATE registry where  the average time was 5 hours and but lagged far 
behind the 1.7 hours of NCDR AR-G registry.(55–57)  This may be attributed to efficient 
ambulance service and awareness in the developed countries whereas such a system is still in it’s 
infancy in rural Vellore.  We also found that men presented earlier to the hospital after symptom 
onset (5.9 hours among men and 9.9 hours among women).  This is comparable to what was 
found by Moser DK et al and may explain worse prognosis in women who suffer STEMI. (58) 
Among risk factors, smoking was the most common (54.6% of men were smokers).  Women had 
higher prevalence of Diabetes and Hypertension compared to men.  This observation is 
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comparable to what was found in the INTERHEART study. Six people (2.8%) had a family 
history of premature coronary artery disease.   
Almost all the men presented with chest pain (98.4%), whereas 12.1% of women had symptoms 
other than chest pain at presentation.  Among both sexes, majority of patients presented in Killip 
class I (79.2% overall) which is comparable to what was observed and published by Grieco et al 
where it was 78.9%.(59) Anterior wall ST-elevation MI (57.9%) was more common than inferior 
wall ST-elevation MI (42.1%). This observation is similar to the study by Kunwar et al.(55)  
INTERVENTION  
One hundred and eleven patients underwent primary PCI (52.3%), followed by thrombolysis-57 
patients (26.4%).  Forty-six patients underwent rescue PCI (21.3%). This rate is much higher 
than what was done in this same institute as published by Kunwar BK et al from 2008 – 2011 
where only 11% among 1905 patients underwent primary PCI.(55) The CREATE registry 
showed a primary PCI rate of 8%.(56)   However, this is still significantly lesser than the west as 
described in the NCDR AR-G registry where the rate was 75.3%.(57)  The recent 
implementation of State Health Insurance Schemes have resulted in higher rate of primary PCI in 
the city.  This was not the case earlier where thrombolysis was the only affordable option 
available.(55) 
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TpTe INTERVAL 
The ∆TpTe (pre TpTe interval -post TpTe interval) was reduced in all the intervention groups, 
and was statistically significant in all the groups. The median pre TpTe interval was 84.5ms and 
the 25th, 50th and 75th percentiles were 80, 84 and 100ms respectively. The median post TpTe 
intervals were 76.7ms (64, 76.7 and 80ms), 75ms (60, 75 and 80ms) and 73.3ms (66.7, 73.3 and 
80ms) respectively in the primary PCI, thrombolysis and rescue PCI groups. This was similar to 
the study by LIN Xiao-ming et al, where the TpTe interval was significantly reduced after PCI in 
patients with severe coronary artery stenosis.(60)  In contrast, in the study by Christian Haarmark 
et al found that the, TpTe interval was prolonged after primary PCI in the survivor group but 
decreased in patients that died during follow up, with a hazard ratio of 10.5.(46)  
The different reperfusion strategies did not confer any advantage with respect to change in TpTe 
interval. There was no previous study that had assessed pre and post TpTe interval in 
thrombolysed patients.  
QT DISPERSION 
The ∆CQTd (pre CQTd -post CQTd) had increased in all three intervention groups, and this 
increase was statistically significant in all the groups. Earlier studies however had  shown that 
though CQTd increased in the early phase of STEMI, it  decreased following reperfusion.(61–
63). This differed from the observation in our study and may relate to the timing of the ECG 
following reperfusion. In our cohort, it was done 90 minutes after reperfusion while in the 
previous studies it was done after longer intervals.(64) Therefore it is plausible that the time 
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period following STEMI is also one of the important determinants of QT interval and its 
dispersion.(65) Additionally the reperfusion strategy employed also differed. 
There was lack of correlation between ∆TpTe (pre TpTe interval -post TpTe interval) and 
∆CQTd (pre CQTd -post CQTd). QT interval encompasses both ventricular depolarization and 
repolarization. Reperfusion restores action potential duration which was reduced during the 
ischemic state resulting in relative prolongation of the ventricular depolarization. This is 
manifested by a change in QRS duration on surface ECG which in turn affects the QT interval. 
The time line in which the changes in QT interval and TpTe interval occurs also differ. 
Bonnenmeier et al has shown that myocardial ischemia and reperfusion initially causes a large 
increase in the QT interval and later there is a decrease but it does not return to baseline values in 
the first 24 hours after reperfusion. The TpTe interval on the other hand was observed to 
decrease within the first 4 hours after PCI. (48) In this study, the post reperfusion ECG was taken 
within 90 minutes and hence identified the change in TpTe interval but was too early to detect 
change in QT interval.  
When we looked at multi-variate correlation between ∆TpTe and various clinical parameters like 
age, gender, duration of presenting complaints, the risk factors, ECG site of infarction, Killip 
class, extent of coronary artery disease(single versus multi-vessel disease) ; only duration of 
symptom and Killip class at presentation showed significant correlation with ∆TpTe.  In the 
study by Christian Haarmark et al also, there was no correlation between TpTe and culprit vessel 
or LVEF.(46)  However, in the study by LIN Xiao-ming et al, TpTe interval was found to 
correlate with the extent and severity of coronary artery disease.(60) Prolonged duration of 
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presentation and higher Killip class are independent risk factors for poor prognosis after 
STEMI.(15)  So it can be assumed that such patients with higher pre TpTe interval will benefit 
maximum from reperfusion therapy, preferably from primary PCI. 
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TpTe INTERVAL AND MAJOR ADVERSE CARDIAC EFFECTS  
As the healthy population has TpTe interval <100 ms, we compared 30-day mortality, heart 
failure and arrhythmias between the two groups of patients with STEMI as those who had pre 
intervention TpTe interval upto 100 ms and those who had pre intervention TpTe interval> 100 
ms.(45)  Though there was  a trend for increased number of deaths (OR – 1.41, 95% CI – 0.29 – 
6.84) and heart failure (OR- 2.14, 95% CI – 0.41 – 11.15) in the group of patients with higher pre 
TpTe interval (> 100 ms), this was not statistically significant. This is in contrast with the study 
of Christian Haarmark et al, where the pre primary PCI TpTe interval predicted all-cause 
mortality. (46) However, Zabel et al assessed TpTe interval after intervention in 280 survivors of 
STEMI and found no significant difference in those who died.(47) 
The association between pre TpTe interval of >100 ms and 30 day mortality was found to be 
significant in this study.   However, the confidence interval of this group was too wide.  
Nonetheless, it predicted a 16% increased risk of arrhythmias.  This was again in agreement with 
other studies which showed that increased TpTe interval was associated with an increase in 
arrhythmias in patients with coronary artery disease and post acute coronary syndrome. (54, 66-
67)   
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CHAPTER 7 
LIMITATIONS 
1. The patients were not followed beyond 30 days. Hence, the conclusion derived from the 
study applies only to Major Adverse Cardiac Events at 30 days. Perhaps, if the cohort was 
followed for a longer period, the positive predictive value of the TpTe interval may have 
become significant.  
2. The TpTe interval was assessed only up to 90 minutes post reperfusion (in patients who were 
lysed) or earlier (patients who under went primary or rescue PCI).  Changes beyond this 
period have not been assessed due to time constraints.  
3. The repolarization indices were calculated only in the ECG leads with non significant ST 
changes (not related to infarct zone). So the effect of ischemia on repolarization may not be 
truly representative of the actual changes.  
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CHAPTER 8 
CONCLUSION 
From this study we can conclude that Pre TpTe interval cannot be used to predict 30 day 
Mortality or heart failure in patients who have suffered ST-segment elevation Myocardial 
Infarction.  However, pre TpTe interval more than 100 ms may be used to predict risk of 
arrhythmias.  
There was statistically significant reduction of TpTe interval and an increase in CQTd in all 
intervention groups at 90 minutes (primary PCI, thrombolysis or rescue PCI).  There was no 
significant association between ∆TpTe interval and ∆CQTd which suggests that one index 
cannot replace the other.  
In this study, ∆TpTe interval was significantly associated with Killip class and duration of chest 
pain at presentation. 
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ANNEXURE I 
CONSENT AND PATIENT INFORMATION SHEET 
Informed Consent form to participate in a research study 
Study Title:  
The prognostic value of T peak to Tend interval on the surface Electrocardiogram in 
patients undergoing reperfusion therapy for ST segment elevation myocardial infarction.   
 
Study Number:  
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
 
 (i) I confirm that I have read/it has been read to me and understood the information 
sheet dated _________ for the above study and have had the opportunity to ask 
questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s 
behalf, the Ethics Committee and the regulatory authorities will not need my permission 
to look at my health records both in respect of the current study and any further research 
that may be conducted in relation to it, even if I withdraw from the trial. I agree to this 
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access. However, I understand that my identity will not be revealed in any information 
released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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PATIENT INFORMATION SHEET 
The prognostic value of Tpeak – Tend interval on the surface Electrocardiogram in 
patients undergoing reperfusion therapy for ST-segment elevation Myocardial 
Infarction 
Dated : March, 2013 
Site: Christian Medical College, Vellore 
Your consent 
You are invited to take part in this research project. The patient information sheet contains 
detailed information about the research project. Its purpose is to explain to you as openly 
and clearly as possible all the procedures involved in this project before you decide whether 
or not to take part in it. 
Please  read this patient information sheet carefully. Feel free to ask questions about any 
information in the statement. Once you understand what the project is about and if you 
agree to take part in it, you will be asked to sign the consent form. By signing the same, 
you do not alter your legal rights, but you indicate that you understand the information and 
that you give your consent to participate in the research project. 
You will be given a copy of both the Consent form and the Patient information sheet to 
keep as a record. 
Alternatives to Participation 
It is important that you understand that your participation in this study must be voluntary. 
This is a research project and you do not have to be involved. If you do not want to 
participate your medical care will not be affected in any way. 
Description of the Project 
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Heart attack (ST-segment elevation Myocardial Infarction) requires immediate treatment.  
The goal of treatment of ST-segment elevation Myocardial Infarction is mechanical 
reperfusion (opening up the blocked coronary artery)- either by primary percutaneous 
coronary intervention (angioplasty) or by pharmacological thrombolysis (medicine to 
dissolve the clot).  The goal of reperfusion is to reduce cardiac death and morbidity.  
Myocardial reperfusion also alters the repolarisation (electrical characteristics) of the 
myocardium(heart muscle).  Post heart attack patients are prone to develop ventricular 
arrhythmias  ( abnormalities in the rate and rhythm of heart) which cause sudden cardiac 
death. There are certain parameters in the surface 12 lead Electrocardiogram which have 
shown clinical promise for the prediction of death and malignant arrhythmias. They can be 
easily calculated without doing any extra tests. However, there has been very few studies in 
the setting of STEMI undergoing  angioplasty, and even fewer on patients undergoing 
thrombolysis. The purpose of the present study is to analyze prospectively, the acute effects 
of reperfusion on TpTe interval( an ECG parameter) and its relationship with the clinical 
outcome of the patients over 30 days from the heart attack.  It will also compare the effect 
of the two modes of reperfusion on the TpTe interval. 
You are invited to participate in this study because you are undergoing a reperfusion 
therapy for heart attack. There will be some extra ECGs taken and some extra parameters 
will be looked into while doing the Echocardiography and Coronary Angiography. You 
will not have any added risk due to the research protocol. You will be asked to follow up 
after 30 days from the time of your heart attack. 
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Possible Benefits 
The study may not directly benefit you. It will however, enable us to understand the ECG 
changes which may predict risk of death after heart attack. These factors may benefit other 
people in the future. 
Possible Risks 
There will be no added risks due to the research protocol. 
Confidentiality and Disclosure of Information 
Any information obtained in connection with this project that can identify you will remain 
confidential. It will only be disclosed with your permission, except as required by law.  If  
you give us your permission by signing the consent form, we plan to publish the results of 
the study in a medical journal.  In any publication, information will be provided in such a 
way that you cannot be identified. 
Results of Project 
Results of your individual tests will be discussed with you at the end of the procedure. 
Further Information of any Problem 
If you require further information or you have any problems concerning this project, you 
can contact Dr. Subhrangshu Dey (phone 0416-2283572) 
Other Issues 
If you wish to discuss aspects of the study with someone who is not directly involved, you 
can also contact the IRB at CMC, Vellore 
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Participation is Voluntary 
Participation is any research project is voluntary. If you do not wish to take part, you are 
not obliged to. If you wish to take part and later change your mind, you are free to 
withdraw from the project at any stage. 
Your decision whether to take part or not, or to take part and then withdraw, will not affect 
your routine treatment, your relationshio with those treating you or your relationship with 
Christian Medical College, Vellore. 
Before you make your decision, you can ask any questions you have about the research 
project. Only sign the consent form once you have had a chance to ask your questions and 
have received satisfactory answers. 
Before deciding whether or not to take part, you may wish to discuss the project with a 
relative or friend or your local health worker.  Feel free to do this. 
If you decide to withdraw from this project, please notify before you withdraw. This will 
allow us to inform you if there are any health risks linked to withdrawing. 
Payment for Participation 
Participation in this study is voluntary and no payment will be made 
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ANNEXURE II 
PROFORMA 
Serial No : 
Name: 
Hospital No: 
Age: 
Sex: 
Phone No: 
 
Chief Presenting complain : 
Duration: 
Diabetes Mellitus: 
Hypertension: 
Smoking: 
Dyslipidemia : 
Family History: 
 
Heart Rate at admission: 
BP at admission: 
Killip Class at admission: 
 
 
ECG  
Site of infarction : 
Maximum ST elevation : 
Lead I II III aVR aVL aVF V1 V2 V3 V4 V5 V6 Avg. 
Pre TpTe              
Post TpTe              
30 Day TpTe              
 
 Pre Post 30 day 
cQtmax    
cQT min    
cQTd    
 
 
Echocardiogram 
LV Ejection Fraction : 
E/A ratio : 
DT : 
IVRT:  
Medial E’ : 
E/E’: 
Lateral E’:  
xv 
 
E/E’ :  
 
Intervention:   
 
 
 
For Primary PCI group 
Vessel/vessels involved: 
Type of lesion: 
Length of lesion: 
TIMI flow before & after PCI: 
TIMI Myocardial perfusion grade before & after PCI: 
Stent used: 
Size of stent:  
 
30 day follow up 
Alive/dead 
Heart Failure 
Arrhythmias 
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ANNEXURE III 
EXPANSION OF ABBREVIATIONS 
∆ : difference between pre and post 
 ACS : Acute coronary syndrome 
 BMS : Bare metal stent 
  CAD : coronary artery disease 
  Cpc : chief presenting complaint 
 cQT : corrected QT interval 
  DES : Drug eluting stent 
  DM : Diabetes mellitus 
  Dyl : Dyslipidemia 
   Fh : Family history 
   HF : Heart failure 
   HTN : Hypertension 
   Inv : Intervention 
   Klp : killip class 
   LVEF : Left Ventricular Ejection Fraction 
 PCI : Percutaneous coronary intervention 
 PCI : Percutaneous transluminal coronary angioplasty 
QTd :  QT dispersion 
  Smk : Smoker 
   STEMI : ST-segment elevation Myocardial infarction 
STR : ST-segment resolution 
  TDR : Transmural dispersion of repolarization 
TIMI : Thrombolysis in Myocardial Infarction 
TMP : TIMI myocardial perfusion 
 TpTe : Tpeak to T end interval 
   
  
xvii 
 
ANNEXURE IV 
MASTER CHART 
Master chart table headings 
id – identification number 
age – age of the patient 
sex – gender of the patient (male -1, female-2) 
cpc – chief presenting comlplaint (1 – chest pain, 2 – others) 
duration – duration of presenting complaint in hours 
dur12hrs – duration of presenting complaint in hours (>12 hours – 1, < 12hours – 2) 
dm -  Did the patient have Diabetes Mellitus? (Yes – 1, No -2) 
htn-  Did the patient have Hypertension? (Yes – 1, No -2) 
smk – Was the patient a smoker? (Yes – 1, No -2) 
dyl - Did the patient have Dyslipidemia? (Yes – 1, No -2) 
fh - Did the patient have family history of premature coronary artery disease? (Yes – 1, No -2) 
klp – Killip class at presentation  
ecg – Electrocardiographic site of infarction (anterior -1, inferior – 2) 
stemax – Maximum ST segment elevation in mV 
pretpte – Pre intervention TpTe interval in ms 
posttpte – Post intervention TpTe interval in ms 
precqtd - Pre intervention cQTd interval in ms 
postcqtd - Post intervention cQTd interval in ms 
lvef – Left Ventricular Ejection Fraction% 
inv – Intervention done (Primary PCI – 1, Lysis -2, Rescue PCI -3) 
ves –Extent of Coronary artery disease (Single -1, Double -2, Triple -3) 
pretimi - Pre intervention TIMI flow (No flow -0, penetration -1, partial flow -2, normal flow -3) 
posttimi - Post intervention TIMI flow (No flow -0, penetration -1, partial flow -2, normal flow -3) 
pretmp – Pre intervention TMP grading (No perfusion – 0, minimal perfusion – 1, Moderate 
perfusion – 2, normal perfusion-3) 
posttmp – Post intervention TMP grading (No perfusion – 0, minimal perfusion – 1, Moderate 
perfusion – 2, normal perfusion-3) 
stent – type of stent used (None -0, BMS -1, DES -2) 
sized –Diameter of stent in mm 
sizel – length of stent in mm 
n30dm – 30 day mortality (Alive -1, Death -2) 
n30dhf – 30 day heart failure (Yes- 1, No -2) 
n30dary - 30 day arrhythmia (Yes- 1, No -2) 
TpTediff – difference between pre & post intervention TpTe 
cQTddiff - difference between pre & post intervention cQTd 
ANNEXURE VI 
MASTER CHART 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
1 56 1 1 5 2 1 2 2 2 0 I 2 2 0.3 80 50 114 
2 45 1 1 2 2 2 2 2 2 0 I 1 1 0.2 100 72.5 74 
3 80 1 1 10 2 1 2 2 2 0 I 1 1 1.1 100 66.7 66 
4 67 1 1 2 2 1 2 2 2 0 I 2 2 0.3 80 40 66 
5 60 1 1 5 2 2 2 1 2 0 I 2 2 0.6 103.3 74.3 43 
6 62 1 1 11 2 2 2 2 2 0 I 1 1 1 84 80 35 
7 50 2 1 8 2 2 2 2 2 0 III 1 1 1 100 76 27 
8 60 1 1 11 2 2 2 1 2 0 I 2 2 0.6 80 75 23 
9 66 1 1 4 2 2 1 2 2 0 I 2 2  100 70 12 
10 53 1 1 7 2 1 2 2 2 0 I 2 2 0.3 120 90 33 
11 39 1 1 24 1 1 1 2 2 1 I 1 1 1 100 100 113 
12 38 1 1 3 2 2 2 2 2 0 I 2 2 0.3 100 80 35 
13 67 1 1 3 2 1 2 1 2 0 I 2 2 0.2 86.7 80 59 
14 62 1 1 2 2 2 1 2 2 0 III 1 1 0.2 86.7 100 33 
15 52 1 1 19 1 2 2 2 2 0 I 1 1  120 70 46 
16 49 1 1 4 2 2 2 1 2 0 I 1 1 1.9 80 80 21 
17 47 1 1 7 2 2 2 2 2 0 I 2 2 0.4 113.3 70 16 
18 62 1 1 2 2 2 1 1 2 0 I 2 2 0.4 100 60 74 
19 71 1 1 1 2 2 2 2 1 0 I 2 2 0.8 93.3 72 28 
20 47 1 1 8 2 2 2 1 2 0 III 1 1 0.3 80 82.8 4 
21 42 1 1 2 2 2 2 2 2 0 I 1 1 0.6 90 73.3 57 
22 49 1 1 2 2 1 2 1 2 0 I 1 1 0.4 80 72 64 
23 69 2 1 8 2 1 2 2 2 0 I 2 2 0.4 80 70 56 
24 30 1 1 2 2 2 2 2 2 0 I 1 1 1 80 66.7 41 
25 70 1 1 13 1 2 2 2 2 0 IV 2 2 0.5 80 86.7 197.8 
26 44 1 1 5 2 2 2 1 2 0 I 2 2 0.2 76 103 44 
27 56 1 1 8 2 1 1 2 2 0 II 1 1 0.5 80 80 32 
28 57 1 1 7 2 1 2 2 2 0 II 1 1 0.3 80 80 26 
29 47 1 1 9 2 2 1 2 2 0 I 1 1 0.4 71.4 60 11 
30 52 1 1 19 1 2 2 1 2 0 I 1 1 0.8 100 93.3 64 
31 56 1 1 1 2 1 1 1 2 0 I 2 2 0.6 86.7 73.3 16 
32 42 1 1 3 2 2 2 1 2 0 I 1 1 0.5 94 40 80 
33 42 1 1 4 2 2 2 2 2 0 I 1 1 0.9 87.5 70 66 
34 74 1 1 12 1 2 2 1 2 0 I 1 1 0.3 103.3 91.4 10 
35 66 2 1 5 2 2 2 2 2 0 I 1 1 0.5 60 50 98 
36 67 1 1 6 2 1 1 2 2 0 I 2 2 0.3 113.3 93.3 43 
37 32 1 1 4 2 2 2 2 2 0 I 1 1 1.9 120 70 89 
38 69 2 1 5 2 2 1 2 2 0 II 1 1 0.5 86.7 86 115 
39 28 1 1 5 2 2 2 1 2 0 I 1 1 3.2 100 68 50 
40 49 1 1 6 2 1 2 1 2 0 I 1 1 1.9 110 90 28 
41 40 1 1 7 2 1 2 1 2 0 I 1 1 0.8 73.3 66.7 64 
42 61 1 1 5 2 2 2 1 2 0 I 2 2 0.4 66.7 70 29 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
43 41 1 1 10 2 1 1 1 2 0 I 2 2 0.9 100 80 75 
44 50 1 1 3 2 2 2 1 2 0 I 1 1 1.1 80 80 60 
45 64 1 1 4 2 1 1 1 2 0 I 1 1 0.9 90 84 100 
46 60 1 1 4 2 1 2 1 2 0 III 2 2 0.4 133.3 140 25 
47 51 1 1 6 2 1 1 2 2 0 I 1 1 1.9 84 65 72 
48 67 2 1 48 1 2 2 2 2 0 I 2 2 0.2 80 80 60 
49 38 1 1 2 2 2 2 1 2 1 I 1 1 1.5 70 60 50 
50 66 1 1 2 2 1 2 1 2 0 I 1 1 2.5 95 84 14 
51 76 1 1 4 2 2 1 2 2 0 I 1 1 1 90 60 72 
52 49 1 1 5 2 2 2 2 2 1 I 1 1 3.6 96 84 120 
53 66 1 1 5 2 1 1 2 2 0 I 1 1 0.4 86.7 86.7 14 
54 55 2 1 9 2 1 2 2 2 0 I 2 2 0.4 90 60 40 
55 24 1 1 7 2 2 2 2 2 0 I 2 2 0.2 100 94.3 34 
56 59 2 1 19 1 2 2 2 2 0 I 1 1 0.8 100 80 133 
57 74 1 1 4 2 2 1 1 2 0 IV 2 2 0.4 90 40 109 
58 54 1 1 6 2 2 1 1 2 0 I 2 2 1.2 100 80 18 
59 44 1 1 1 2 2 2 1 2 0 I 2 2 1.1 106.7 82.5 16 
60 50 1 1 4 2 2 2 1 2 0 I 1 1 1.2 120 100 10 
61 61 1 1 4 2 2 2 1 2 0 I 2 2 0.4 100 100 90 
62 73 1 1 4 2 2 1 2 2 0 I 2 2 2.1 80 60 50 
63 33 1 1 3 2 2 2 1 2 0 I 2 2 0.6 90 88.9 12 
64 47 1 1 2 2 2 2 1 2 0 II 1 1 1 120 80 130 
65 38 1 1 3 2 2 2 1 2 0 I 1 1 0.7 84 73.3 62 
66 62 1 2 3 2 1 2 2 2 0 IV 1 1  120  156 
67 58 1 1 1 2 1 2 2 2 0 I 2 2 0.9 80 60 40 
68 66 2 1 5 2 2 2 2 2 0 II 1 1 0.3 90 60 110 
69 51 1 1 4 2 2 2 1 2 0 II 1 1 0.3 70 60 110 
70 59 1 1 2 2 2 2 1 2 0 I 2 2 0.6 90 70 43 
71 37 1 1 1 2 1 2 1 2 0 I 2 2 0.8 113.3 68.5 11 
72 70 2 1 3 2 2 2 2 2 0 I 2 2 0.6 110 65.8 69 
73 57 1 1 4 2 1 1 2 1 0 I 1 1 0.5 80 72 94 
74 47 1 1 1 2 2 1 1 2 0 I 1 1 0.5 100 92.5 1 
75 45 1 1 4 2 2 2 1 2 0 I 2 2 0.7 80 80 67 
76 66 1 1 6 2 2 2 1 2 1 I 1 1 1.3 96 80 115 
77 51 1 1 4 2 1 1 1 1 0 I 2 2 0.3 120 85 80 
78 70 2 1 15 1 2 2 2 2 0 II 1 1 1.2 80 90 37 
79 58 1 1 2 2 2 1 1 2 0 I 2 2 1.5 80 80 13 
80 45 1 1 1 2 2 2 2 2 0 III 1 1 0.4 100 80 41 
81 38 1 1 6 2 2 2 1 2 0 I 1 1 0.5 80 71.4 90 
82 50 1 1 2 2 2 2 2 2 0 IV 1 1  80 73.3 75 
83 60 1 1 8 2 2 1 1 2 0 I 1 1 1.3 80 40 10 
84 80 1 1 2 2 1 1 2 2 0 I 1 1 2.5 80 66.7 46 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
85 39 1 1 3 2 1 1 1 2 0 I 1 1 0.3 75 60 45 
86 41 1 1 6 2 1 2 1 2 0 I 2 2 0.3 80 93.3 15 
87 60 2 1 4 2 1 2 2 2 0 I 1 1 0.9 80 60 34 
88 61 1 1 4 2 1 1 1 1 1 I 1 1 0.6 93.3 80 28 
89 80 2 1 7 2 1 2 2 2 0 I 2 2 0.6 100 100 30 
90 61 1 1 5 2 1 1 1 2 0 I 2 2 0.4 113.3 100 19 
91 35 1 1 2 2 2 2 1 2 0 II 1 1 2.3 75 60 46 
92 64 1 1 5 2 1 1 1 2 0 I 1 1 2 140 50 11 
93 52 1 1 7 2 1 2 1 2 0 I 1 1 0.2 97.5 83.3 11 
94 57 1 1 2 2 2 2 1 2 0 IV 2 2 0.4 120 80 42 
95 50 1 1 5 2 1 2 2 2 0 I 1 1 1.2 100 84 12 
96 43 1 1 3 2 2 1 2 2 0 I 2 2 0.4 93.3 66.7 10 
97 58 1 1 5 2 2 1 1 2 0 I 1 1 1.5 105 100 28 
98 80 2 1 2 2 1 1 2 1 0 I 1 1 1 110 93.3 40 
99 63 1 1 14 1 1 2 2 2 0 I 1 1 1.1 88 80 33 
100 55 1 1 3 2 2 1 2 2 0 I 1 1 1.6 80 63.3 57 
101 50 1 2 10 2 2 2 2 2 0 I 2 2 0.5 72 56.7 60 
102 50 1 1 19 1 1 2 2 2 0 I 2 2 0.2 96.7 80 27 
103 43 1 1 6 2 2 2 2 2 0 I 1 1 0.2 86.7 80 68 
104 46 1 1 5 2 2 1 1 2 0 I 1 1 1.2 66.7 60 16 
105 70 1 1 8 2 2 2 1 2 0 I 2 2 0.3 85 76.7 46 
106 32 1 1 1 2 2 2 1 2 0 I 2 2 0.9 86.7 65 72 
107 47 1 1 3 2 1 1 2 2 0 I 1 1 0.7 90 65.8 32 
108 50 1 1 3 2 1 1 2 2 0 I 1 1 0.5 80 80 22 
109 47 1 1 7 2 2 1 1 2 0 I 2 2 0.9 90 84 62 
110 31 1 1 1 2 2 2 1 2 0 I 1 1 5 80 68.5 72 
111 49 1 1 6 2 2 2 2 2 0 I 2 2 0.2 80 77.1 60 
112 53 1 1 1 2 2 1 1 2 0 I 1 1 1.8 80 75 30 
113 65 1 1 3 2 1 2 2 2 0 I 2 2 0.8 80 66.7 67 
114 48 1 1 4 2 2 2 1 2 0 I 2 2 0.2 80 80 12 
115 53 1 1 5 2 2 2 2 1 0 I 1 1  80 54.3 66 
116 45 1 1 14 1 2 2 2 2 0 I 1 1 0.3 64 53.3 55 
117 48 1 1 3 2 2 2 1 2 0 II 1 1 1.5 80 60 56 
118 58 1 1 1 2 2 2 1 2 0 I 2 2 0.7 73.3 60 52 
119 38 1 1 8 2 1 2 1 2 0 I 1 1 0.5 73.3 55 90 
120 76 1 1 2 2 1 2 2 2 0 I 2 2 0.3 70 60 20 
121 45 1 1 11 2 1 2 1 1 0 I 2 2 0.3 62.5 50 49 
122 71 1 1 5 2 2 2 2 2 0 I 1 1 0.5 100 88 21 
123 57 1 1 4 2 1 2 1 2 0 I 2 2 0.6 93.3 80 15 
124 43 1 1 7 2 1 1 1 2 0 I 2 2 0.6 80 55 15 
125 38 1 1 13 1 2 2 1 2 0 II 1 1 0.5 90 64 96 
126 67 1 1 2 2 2 2 1 2 0 I 2 2 0.8 80 64 50 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
127 57 1 1 5 2 2 1 1 2 0 II 2 2 0.5 66.7 53.3 54 
128 66 1 1 3 2 2 2 1 2 0 II 1 1 1.2 120 100 79 
129 33 1 1 6 2 2 2 2 2 0 I 1 1 0.2 68 57.1 58 
130 65 1 1 3 2 2 2 1 2 0 I 2 2 0.2 60 55 23 
131 59 1 1 22 1 2 1 2 2 0 I 1 1 0.8 66.7 60 118 
132 50 2 1 2 2 1 2 2 2 0 I 2 2 0.2 100 48 86 
133 51 1 1 3 2 1 2 2 2 0 I 1 1 0.6 68 55 39 
134 63 1 1 4 2 2 2 1 2 0 I 2 2 0.6 60 55 83 
135 60 1 1 5 2 2 2 1 2 0 II 1 1 0.3 80 73.3 66 
136 53 1 1 1 2 2 1 2 2 0 I 1 1 0.8 86.7 46.7 50 
137 52 1 1 4 2 1 1 2 2 0 I 2 2 0.4 100 80 84 
138 76 2 1 2 2 2 2 2 2 0 I 1 1 0.4 66.7 40 104 
139 50 2 1 11 2 1 2 2 2 0 I 1 1 0.4 70 66.7 80 
140 65 2 1 4 2 2 1 2 2 0 I 2 2 0.2 70 64 89 
141 62 1 1 3 2 1 2 1 2 0 I 1 1 0.8 93.3 80 59 
142 63 1 2 2 2 2 2 1 2 0 I 2 2 0.3 80 66.7 20 
143 65 2 2 7 2 1 1 2 2 0 II 1 1 1 65 60 102 
144 55 2 1 12 1 1 2 2 2 0 II 1 1 1.1 75 70 46 
145 51 1 1 12 1 1 1 2 2 0 I 1 1 1 63.3 55 26 
146 65 1 1 4 2 2 2 2 2 0 II 1 1 0.6 82.28 80 87 
147 52 1 1 5 2 2 2 1 2 0 I 1 1 0.6 80 73.3 96 
148 40 1 1 12 1 2 1 1 2 0 I 2 2 0.3 86.7 80 50 
149 49 1 1 4 2 2 2 1 2 0 I 1 1 0.9 80 72 13 
150 72 1 1 6 2 2 1 1 2 0 I 1 1 1.2 80 80 82 
151 57 1 1 22 1 1 1 2 2 0 I 2 2 0.3 80 75 2 
152 40 1 1 5 2 2 2 2 2 0 I 1 1 0.2 80 66.7 5 
153 46 1 1 9 2 1 2 2 2 0 I 1 1 0.9 80 80 38 
154 65 1 1 1 2 2 1 1 1 0 II 2 2 0.8 80 86.7 4 
155 24 1 1 2 2 2 2 1 2 0 II 1 1  100 60 156 
156 52 1 1 15 1 2 1 1 2 0 I 1 1  110 80 26 
157 53 1 1 2 2 2 2 1 2 0 I 1 1 2.1 110 100 42 
158 52 1 1 14 1 1 1 2 2 0 II 1 1  80 60 44 
159 75 1 1 6 2 2 2 1 2 0 I 2 2  100 80 98 
160 55 1 1 8 2 2 2 1 2 0 IV 1 1 2 100 100 140 
161 65 2 2 3 2 1 1 2 2 0 III 1 1 0.3 80 60 63 
162 60 1 1 5 2 1 1 1 2 0 III 2 2 0.3 80 73.3 55 
163 75 1 1 7 2 1 1 2 2 0 I 1 1 0.5 86.7 80 108 
164 65 1 1 2 2 2 2 2 2 0 II 1 1 1.3 80 60 77 
165 52 1 1 2 2 1 2 2 2 0 I 1 1 0.8 80 66.7 66 
166 65 1 1 4 2 2 1 1 2 0 I 1 1 0.3 80 70 9 
167 60 1 1 14 1 2 1 2 2 0 I 1 1 0.8 90 80 55 
168 55 2 2 6 2 1 1 2 2 0 I 2 2 0.7 80 60 3 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
169 42 1 1 24 1 1 1 2 2 0 I 2 2 0.3 80 80 18 
170 65 1 1 5 2 1 1 2 2 0 I 1 1 0.4 85 80 39 
171 50 1 1 6 2 2 2 2 2 0 I 2 2  100 60 26 
172 53 1 1 24 1 2 1 2 2 0 I 1 1  110 80 76 
173 35 1 1 8 2 2 2 1 2 0 I 1 1  84 80 26 
174 70 1 1 23 1 1 2 2 2 0 I 1 1  80 90 106 
175 54 1 1 4 2 2 2 2 2 0 I 2 2  100 80 65 
176 34 1 1 3 2 2 2 1 2 0 I 1 1 0.2 80 57.1 115 
177 73 1 1 12 1 1 2 2 2 0 I 2 2 0.2 96 75 80 
178 49 1 1 1 2 2 2 1 2 0 I 1 1 1.6 86.7 80 26 
179 59 2 1 2 2 1 1 2 2 0 I 1 1 1.4 80 60 46 
180 41 1 1 18 1 1 1 2 2 0 I 2 2 0.6 93.3 73.3 62 
181 80 1 1 5 2 2 2 1 2 0 I 2 2  100 80 95 
182 47 1 1 10 2 2 2 2 2 0 I 1 1 2 140 100 24 
183 61 1 1 3 2 2 1 2 2 0 I 2 2 0.3 77.5 76.7 76 
184 77 1 1 2 2 1 1 1 2 0 I 2 2 0.2 80 80 139 
185 47 1 1 4 2 2 2 1 2 1 II 1 1  100 80 110 
 186 62 1 1 4 2 1 2 2 2 0 IV 1 1 1.3 104 100 156 
187 55 2 1 13 1 1 1 2 2 0 II 1 1 1.1 88 80 105 
188 67 2 1 4 2 2 1 2 2 0 II 1 1 0.4 80 60 38 
189 53 2 1 2 2 1 2 2 2 0 I 1 1 0.5 80 73.3 46 
190 57 2 1 16 1 2 1 2 2 0 I 2 2  84 80 49 
191 45 1 1 6 2 2 2 1 2 0 I 2 2 0.3 90 80 10 
192 77 1 1 10 2 1 1 2 2 0 I 2 2 0.2 80 66.7 4 
193 47 2 1 28 1 2 2 2 2 0 I 2 2 0.3 80 60 53 
194 60 1 1 3 2 2 2 2 2 0 I 2 2 0.3 80 70 8 
195 55 2 1 4 2 1 2 2 2 0 I 2 2 0.3 110 100 32 
196 52 1 1 16 1 1 1 2 2 0 I 1 1  80 90 83 
197 71 2 2 25 1 1 1 2 2 0 II 1 1 2.2 80 65 9 
198 70 2 1 24 1 1 1 2 2 0 I 2 2 0.5 80 80 62 
199 48 1 1 3 2 2 1 1 2 0 II 1 1 2.5 84 80 17 
200 60 2 1 5 2 2 1 2 2 0 I 2 2 1.4 100 90 4 
201 55 1 1 11 2 2 1 1 2 0 I 2 2  80 80 40 
202 52 1 1 2 2 1 1 1 2 0 I 2 2 2 80 60 5 
203 38 1 1 12 1 2 2 1 2 0 I 1 1  120 70 108 
204 51 1 1 3 2 1 2 2 2 0 I 1 1 0.9 80 76 40 
205 48 1 1 10 2 2 1 1 2 0 II 1 1 0.9 86.7 80 9 
206 68 2 1 10 2 2 1 2 2 0 I 1 1 2 80 60 47 
207 32 1 1 4 2 2 2 1 2 0 II 1 1 2 80 70 47 
208 80 2 1 8 2 1 2 2 2 0 IV 2 2 0.5 104 100 150 
209 35 1 1 6 2 2 2 1 2 0 IV 1 1 3 90 80 125 
210 60 1 1 3 2 1 1 2 2 0 I 2 2 0.7 100 80 37 
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id age sex cpc duration dur12hrs dm htn smk dyl fh klp ecg site stemax pretpte posttpte precqtd 
211 60 1 1 5 2 2 1 1 2 0 II 1 1 2.2 80 73.3 29 
212 65 1 1 3 2 2 1 2 2 0 II 2 2 0.9 93.3 76.7 112 
213 50 1 1 2 2 2 2 2 2 0 I 2 2 1.9 100 86.7 19 
214 54 1 1 5 2 1 2 2 2 0 I 2 2 0.3 80 76.7 41 
215 53 1 1 5 2 2 2 1 2 0 I 2 2 0.8 100 66.7 44 
216 38 1 1 1 2 2 2 1 2 0 I 1 1 2.2 100 66.7 22 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
1 170 48 1 3 0 2 0  2 3 24 1 2 2 30 -56 
2 32 42 2         1 2 2 27.5 42 
3 49 37 1 1 0 2 0 1 2 3 18 1 2 2 33.3 17 
4 70 53 3 1 0 2 1 1 2 3.5 23 1 2 2 40 -4 
5 50 58 3 1 1 2 2 2 2 3.5 24 1 2 2 29 -7 
6 62 36 1 1 0 1   2 3.5 21 1 2 2 4 -27 
7 40 40 2         1 2 2 24 -13 
8 144 39 2         1 2 2 5 -121 
9 20 54 1 3 0 2   2 3.5 18 1 2 2 30 -8 
10 32 42 3 2 0 2 0 1 2 3.5 14 1 2 2 30 1 
11 74 46 1 2 0 2 1  0   1 2 2 0 39 
12 51 54 1 1 0 2   2 3 18 1 2 2 20 -16 
13 48 49 2         1 2 2 6.7 11 
14 116 32 2 1        1 2 2 -13.3 -83 
15 76 54 1 1 0 2   2 3.5 16 1 2 2 50 -30 
16 125 32 3 2 0 2 1 1 1 3 18 1 2 2 0 -104 
17 44 51 3 1 0 1 0 0 0   1 2 2 43.3 -28 
18 86 53 2         1 2 2 40 -12 
19 34 50 1 2 0 2 0 1 1 3 18 1 2 2 21.3 -6 
20 50 35 1 2 0 2 0 0 2 2.5 18 2 1 2 -2.8 -46 
21 26 37 1 1 0 2 0 1 1 3.5 18 1 2 2 16.7 31 
22 60 33 3 1 0 2 1 1 1 2.75 18 1 2 2 8 4 
23 132 46 3 3 0 2 0 1 2 2.75 12 1 2 2 10 -76 
24 98 44 3         1 2 2 13.3 -57 
25 223 25 2         2 1 2 -6.7 -25.2 
26 54 58 1 1 0 2 0  0   1 2 2 -27 -10 
27 45 42 1 3 0 2 0 0 2 2.5 33 1 2 2 0 -13 
28 44 37 2 3        1 2 2 0 -18 
29 9 48 1 1 0 2 1 1 2 3 18 1 2 2 11.4 2 
30 55 32 1 2 0 2 0 1 1 2.75 18 1 2 2 6.7 9 
31 23 53 1 2 0 2 0 1 2 3.5 28 1 2 2 13.4 -7 
32 109 49 2         1 2 2 54 -29 
33 65 44 1 2 0 2 0 1 1 3 26 1 2 2 17.5 1 
34 14 33 1 2 0 2 1  1 3 21 1 2 2 11.9 -4 
35 99 35 2         1 2 2 10 -1 
36 46 49 1 3 0 2   2 2.5 18 1 2 2 20 -3 
37 60 57 3 1 1 2 1 2 1 3.5 18 1 2 2 50 29 
38 100 37 3 1 0 2 0 1 1 3 18 1 2 2 0.7 15 
39 34 43 1 1 0 2 0 2 2 3.5 16 1 2 2 32 16 
40 37 43 2         1 2 2 20 -9 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
41 95 43 1 1 0 2 0 2 2 3 24 1 2 2 6.6 -31 
42 48 54 2         1 2 2 -3.3 -19 
43 101 64 1 2 0 2 2 2 1 3 32 1 2 2 20 -26 
44 95 44 2         1 2 2 0 -35 
45 87 44 2         1 2 2 6 13 
46 87 51 2         1 2 2 -6.7 -62 
47 90 32 1 1 0 2 0 1 2 2.75 21 1 2 2 19 -18 
48 55 49 1 1 0 2 2 2 1 2.75 32 1 2 2 0 5 
49 30 49 1 3 0 2 0 2 1 3.5 15 1 2 2 10 20 
50 25 40 2         1 2 2 11 -11 
51 38 38 2         1 2 2 30 34 
52 100 39 1 3 1 2 0 1 0   1 2 2 12 20 
53 50 45 2         1 2 2 0 -36 
54 20 60 2 3        1 2 2 30 20 
55 68 53 3 1 0 2 1  0   1 2 2 5.7 -34 
56 108 44 2         1 2 2 20 25 
57 150 49 2 3        1 2 2 50 -41 
58 19 46 3 2 0 2 0  1 2.75 15 1 2 2 20 -1 
59 70 50 2         1 2 2 24.2 -54 
60 18 36 1 1 0 2 0 2 2 4 16 1 2 2 20 -8 
61 98 42 2         1 2 2 0 -8 
62 90 51 2         1 2 2 20 -40 
63 92 48 1 1 0 2 2 2 2 2.75 12 1 2 2 1.1 -80 
64 116 37 1 3 0 2 0 2 2 3.5 18 1 2 2 40 14 
65 74 45 3 1 0 2 0 1 1 3.5 25 1 2 2 10.7 -12 
66  30 2         2 2 2   
67 70 56 1 3 0 2 0  1 3.5 40 1 2 2 20 -30 
68 70 37 2         1 2 2 30 40 
69 60 38 1 1 0 2 0  2 3 21 1 2 2 10 50 
70 29 58 3 3        1 2 2 20 14 
71 3 41 1 1 0 2 1  2 3 23 1 2 2 44.8 8 
72 118 43 3 1 0 2 0  1 2.75 20 1 2 2 44.2 -49 
73 41 45 2 3        1 2 2 8 53 
74 55 43 1 2 0 2 0 2 2 2.75 23 1 2 2 7.5 -54 
75 148 62 2         1 2 2 0 -81 
76 46 41 1 1 0 2 0 1 2 3 24 1 2 2 16 69 
77 67 49 1 2 0 2 2 2 2 2.5 28 1 2 2 35 13 
78 123 40 1 2 0 2 0  2 2.75 18 1 2 2 -10 -86 
79 4 41 3 2 0 2 0 2 2 3 38 1 2 2 0 9 
80 35 47 3 3 0 2   2 2.75 18 1 2 2 20 6 
81 105 45 3 1 1 2 1 2 2 3.5 18 1 2 2 8.6 -15 
82 26 44 1 1 0 2 0 1 2 3 18 1 2 2 6.7 49 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
83 21 40 3 1 0 2 0 0 2 3.5 24 2 2 2 40 -11 
84 25 32 1 1 0 2 0 2 1 3.5 13 1 2 2 13.3 21 
85 15 37 3 1 0 2 0 2 1   1 2 2 15 30 
86 12 56 1 2 0 2 0  2 2.5 18 1 2 2 -13.3 3 
87 16 39 2         1 2 2 20 18 
88 117 39 1 1 0 2 0 1 2 4 23 1 2 2 13.3 -89 
89 31 22 1 3 0 2 0 0 2 2.75 23 2 1 2 0 -1 
90 23 49 1 2 0 2 1 2 2 2.75 16 1 2 2 13.3 -4 
91 58 49 1 1 0 2 0 2 1 3.5 22 1 2 2 15 -12 
92 69 28 1 3 0 2   0   1 1 2 90 -58 
93 53 46 3 3 0 2 1 2 1 2.75 12 1 2 2 14.2 -42 
94 57 56 3 2 0 2 0 1 1 3.5 26 1 2 2 40 -15 
95 122 40 1 1 0 2 0 1 2 3 21 1 2 2 16 -110 
96 73 51 3 2 0 2   2 3 40 1 2 2 26.6 -63 
97 74 41 3 1 0 2 0 2 1 3 18 1 2 2 5 -46 
98 40 39 1 1 0 2 0 1 2 3.5 24 1 2 2 16.7 0 
99 54 34 1 1 0 2   2 3 28 1 2 2 8 -21 
100 80 38 1 2 0 2 0 2 2 2.75 40 1 2 2 16.7 -23 
101 28 52 1 2 0 2 0  1 3 23 1 2 2 15.3 32 
102 48 59 1 3 0 2 0  1 3 23 1 2 2 16.7 -21 
103 90 45 1 3 0 2 0 1 1 3 18 1 2 2 6.7 -22 
104 48 34 1 2 0 2 0  2 3 16 1 2 2 6.7 -32 
105 55 47 3 2 1 2 0 0 1 3.5 18 1 2 2 8.3 -9 
106 76 51 1 1 0 2 0 1 0   1 2 2 21.7 -4 
107 80 46 3 1 0 2 1 1 2 3.5 18 1 2 2 24.2 -48 
108 45 41 3 2 1 1 0 0 1 2.75 23 1 2 2 0 -23 
109 85 48 3 1 1 2 1  1 3.5 28 1 2 2 6 -23 
110 66 52 3  2 2 2  0   1 2 2 11.5 6 
111 40 54 3 1 1 2 1  1 2.75 28 1 2 2 2.9 20 
112 3 35 2         1 2 2 5 27 
113 21 45 1 2 0 2 0  2 3 32 1 2 2 13.3 46 
114 4 41 2         1 2 2 0 8 
115 76 43 2 1        1 2 2 25.7 -10 
116 44 39 2         1 2 2 10.7 11 
117 82 38 1 1 0 2 1 2 1 3 12 1 2 2 20 -26 
118 38 48 1 2 0 2   2 3.5 18 1 2 2 13.3 14 
119 80 38 3 3 1 2 0 1 2 3.5 40 1 2 2 18.3 10 
120 65 46 1 2 1 2 0 2 2 3 33 1 2 2 10 -45 
121 75 54 2         1 2 2 12.5 -26 
122 48 38 1 3 0 1 0  2 3 23 1 2 2 12 -27 
123 12 43 1 3 0 2 0 1 2 3.25 18 1 2 2 13.3 3 
124 11 56 1 1 0 2 0 2 2 3.5 18 1 2 2 25 4 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
125 117 40 1 1 0 2 2 2 2 3 18 1 2 2 26 -21 
126 60 42 1 1 0 2 0  2 3 23 1 2 2 16 -10 
127 84 39 3 2 0 2 0 2 2 3 12 1 2 2 13.4 -30 
128 122 33 1 2 0 2 2 2 1 3 23 1 2 2 20 -43 
129 54 44 1 1 0 0 0  0   1 2 2 10.9 4 
130 38 57 2         1 2 2 5 -15 
131 106 35 1 3 0 2 0 1 0   1 2 2 6.7 12 
132 17 58 2         1 2 2 52 69 
133 48 40 1 1 0 1 2 2 1 3.5 23 1 2 2 13 -9 
134 44 56 2         1 2 2 5 39 
135 35 33 2         1 2 2 6.7 31 
136 24 50 3 1 0 2 0 1 1 3.5 23 1 2 2 40 26 
137 76 56 3 1 0 2 1 1 1 2.75 12 1 2 2 20 8 
138 109 48 1 3 0 2 0 1 2 3 15 1 2 2 26.7 -5 
139 112 34 1 2 0 2 0  1 3 23 1 2 2 3.3 -32 
140 65 54 1 3 0 2 0 2 2 3 40 1 2 2 6 24 
141 39 42 2 1        1 2 2 13.3 20 
142 32 52 1 2 0 2 0 2 2 3.5 18 1 2 2 13.3 -12 
143 70 41 1 1 0 2 0  2 3 24 1 2 2 5 32 
144 129 40 2 2     1   2 2 1 5 -83 
145 44 40 1 3 0 2 0  1 2.75 15 1 2 2 8.3 -18 
146 76 43 2         1 2 2 2.28 11 
147 117 42 3 1 0 2 0  1 2.5 18 1 2 2 6.7 -21 
148 32 55 3 2 0 2 0  2 2.75 18 1 2 2 6.7 18 
149 27 40 1 1 0 2 0 1 2 3 20 1 2 2 8 -14 
150 40 37 3 2 0 2 1 1 2 3 24 1 1 2 0 42 
151 111 54 1 1 1 2   2 2.75 28 1 2 2 5 -109 
152 68 45 3 1 0 2 0 0 1 3 15 1 2 2 13.3 -63 
153 37 40 1 1 0 2 0 1 2 3 16 1 2 2 0 1 
154 69 50 2         1 2 2 -6.7 -65 
155 213 30 2         1 2 2 40 -57 
156 72 34 1 3 0 2   1 3 20 1 2 2 30 -46 
157 34 38 1 1 0 2   1 3 15 1 2 2 10 8 
158 64 48 1 1 0 2   2 3.5 42 1 2 2 20 -20 
159 85 42 1 3 0 2   1 3.5 28 1 2 2 20 13 
160 22 42 1 3 0 1 0 0   2 1 2 0 118  
161 92 41 2         1 2 2 20 -29 
162 54 40 2 3        1 2 2 6.7 1 
163 138 51 2         1 2 2 6.7 -30 
164 52 43 2         1 2 2 20 25 
165 38 46 1 2 0 2 0  2 2.75 38 1 2 2 13.3 28 
166 115 46 2         1 2 2 10 -106 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
167 134 42 1 1 0 2 0 1 2 2.75 24 1 2 2 10 -79 
168 28 56 1 2 0 2 0 2  2 2 2 20 -25 
169 27 43 1 3 0 2 2 2 2 3 32 1 2 2 0 -9 
170 37 30 1 3 0 2 0 0 1 3 30 2 2 2 5 2 
171 107 55 1 2 0 2   2 3 16 1 2 2 40 -81 
172 63 46 3 2 1 2   1 3 28 1 2 2 30 13 
173 22 41 3 1     0   1 2 2 4 4 
174 70 39 1 2 0 2   2 2.75 28 1 2 2 -10 36 
175 38 51 2         1 2 2 20 27 
176 56 45 3 3 0 2 0  2 3 24 1 2 2 22.9 59 
177 177 49 2         1 2 2 21 -97 
178 94 61 1 1 0 2 0 1 2 3 23 1 2 2 6.7 -68 
179 192 41 1 3 0 2 0  2 2.75 24 1 2 2 20 -146 
180 172 56 1 1 0 2   2 3 12 1 2 2 20 -110 
181 68 42 1 3 0 2   2 3 32 1 2 2 20 27 
182 29 56 1 2 0 2 0 1 2 3 20 1 2 2 40 -5 
183 180 44 1 2 0 2 1 2 1 2.75 24 1 2 2 0.8 -104 
184 239 45 1 3 0 2 0  1 3.5 22 1 2 2 0 -100 
185 76 37 1 1 0 2   2 3 32 1 2 2 20 34 
186 46  2         2 1 1 4 110 
187 25 54 1 1 0 2 0 0 2 3 21 1 2 2 8 80 
188 33 40 2 3        1 2 2 20 5 
189 55 35 2         1 2 2 6.7 -9 
190 20 54 1 1 0 2 0 1 2 3.5 18 1 2 2 4 29 
191 75 56 3 1 1 2 0 0 2 3.5 28 1 2 2 10 -65 
192 40 56 1 2 0 2 2 2 1 2.75 23 1 2 2 13.3 -36 
193 41 50 1 1 0 2 0 1 1 2.75 23 1 2 2 20 12 
194 48 46 1 1 0 2   1 2.5 14 1 2 2 10 -40 
195 27 54 3 2 1 2 1 2 1 2.75 18 1 2 2 10 5 
196 76 54 1 1 0 2   2 2 18 1 2 2 -10 7 
197 37 42 1 1 0 2 0 0 0   1 2 2 15 -28 
198 29 50 1 1 0 2 0 1 2 3 33 1 2 2 0 33 
199 41 41 1 2 0 2 0 0 2 3 24 1 2 2 4 -24 
200 33 45 1 2 0 2 0  1 3.5 26 1 2 2 10 -29 
201 130 36 2         1 2 2 0 -90 
202 34 54 1 2 0 2 0 0 2 3.5 18 1 2 2 20 -29 
203 86 34 3 1 0 2   1 3.5 26 1 2 2 50 22 
204 41 42 2         1 2 2 4 -1 
205 71 38 1 1 0 2 0  2 3 21 1 2 2 6.7 -62 
206 60 49 1 2 0 2 0 1 2 3.5 24 1 2 2 20 -13 
207 50 45 1 1 0 2 2 2 2 3.5 18 1 2 2 10 -3 
208 89 29 1 3 0 1 0   3 23 1 2 1 4 61 
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id postcqtd lvef inv ves Pretimi Posttimi Pretmp Posttmp stent sized sizel n30dm n30dhf n30dary TpTediff cQtddiff 
209 85 20 1 2 0 0 0  2   2 1 2 10 40 
210 129 54 2         1 2 2 20 -92 
211 61 50 1 1 0 2 2 2 2 2.75 12 1 2 2 6.7 -32 
212 5 45 2         1 2 2 16.6 107 
213 88 55 1 2 0 2 0 1 2 3 18 1 2 2 13.3 -69 
214 49 56 1 1 0 2 0 2 2 3 23 1 2 2 3.3 -8 
215 55 55 3 1 0 1   1 2.75 26 1 2 2 33.3 -11 
216 55 26 3 1 1 2   2 3 28 1 2 2 33.3 -33 
 
